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A b stract
Certain mouse models of Cystic fibrosis (CF) exhibit a severe intestinal phenotype,
resulting in death soon after birth or at the time of weaning. Marked variations in intestinal
disease severity among different CF mouse models have suggested a prominent role for
secondary genetic modifiers of the disease. Calcium-activated, chloride channels (CLCA) have
been postulated as genetic modifiers of CF. It has been previously shown that mCLCA3, a
secreted protein involved in mucus production, shows markedly reduced expression in goblet
cells of the intestines of a CF mouse model, and when expression is corrected through transgenic
manipulation, can significantly ameliorate the disease. Current studies were undertaken using
quantitative RT-PCR to show that expression of mClca6 is significantly reduced (p<0.005) in the
ileum of a juvenile CF mouse model. Further quantitative RT-PCR studies were performed on
the mildly-affected adult CF mice, showing significant differential expression of mClca6 in the
jejunum (p<0.005), but not in the ileum. Moreover, a CF mouse model which exhibits relatively
mild lung and intestinal disease compared to other mouse models shows no significant
differential expression of mClca6 in the ileum. Although the function of mCLCA6 remains
unclear, these results provide support for it as a potential modifier of intestinal disease severity.

Key words: mCLCA 6, mouse model, ileum, Cystic fibrosis (CF), modifier genes
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I.

In trod u ction

I. A. Clinical features of Cystic fibrosis
Cystic fibrosis (CF), with a carrier frequency of 1 in 25, is the most common lethal
autosomal-recessive disorder affecting the Caucasian population (1). The disease involves the
over-production and accumulation of mucus from fluid secreting epithelial cells throughout
many organs in the body. The severe or complete loss o f function of the CF Transmembrane
Conductance Regulator (CFTR) is the sole cause of CF (2, 3). The CFTR functions primarily as
a cAMP-dependent ion channel, whose role is to regulate chloride (Cl- ) transmission/transport
across the apical membrane of epithelial cells. More recently, it has been implicated as a
regulator of other epithelial ion channels (1,4 and reviewed in (5)). Mutations within the CFTR
disrupt Cl" transport, resulting in the culmination of thick mucus and impaired mucociliary
clearance ( 1).
The average life expectancy of CF patients is 33 years (4); the range of symptoms,
however, from mild cases of recurrent sinusitis in adulthood to death in early childhood, denotes
a patient-specific prognosis (6). Classically, the multi-system disease manifests itself as an
accumulation of thick mucus lining the exocrine ducts o f the respiratory tract, intestines, liver,
reproductive tract, pancreas and sweat glands (4). The high viscosity abates the ability of ciliated
epithelial cells to efficiently clear the mucus, arising in compromised breathing, pancreatic
insufficiency, intestinal blockage and a rich breeding ground for bacteria (1,4). It is estimated
that 90% of patients will succumb to respiratory infection and inflammation, though chronic
intestinal and liver complications may also contribute. An in-depth look at the clinical
presentation o f CF is given in detail below.
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I. A. i. Respiratory system
Respiratory failure, secondary to chronic bacterial infections, accounts for 95% of
mortality in CF patients (4). It is largely considered to be the most variable of all the CF
symptoms, with age of first infection, degree of bronchiectasis and rate of pulmonary decline
presenting as patient-specific (8, and reviewed in (7)). Similar to many recessive metabolic
diseases, the lungs of CF patients appear morphologically and histologically normal at birth, but
within weeks symptoms appear and progressively worsen over their lifetime (9, 10). The
respiratory tract is in a constant state of mucus clearance in order to eliminate the bacteria which
deposit during normal breathing (11). Over time, the airways and lungs of CF patients eventually
become congested with accumulated mucus, which hinders breathing and provides a rich
breeding ground for opportunistic bacteria (reviewed in (5)). During childhood, Haemophilus
influenzae and Staphylococcus aureus infections predominate, eventually leading to colonization
by the aggressive strain Pseudomonas aeruginosa in early adulthood; 40-90% of patients suffer
from chronic P. aeruginosa infections, which have been linked to progressive and irreversible
lung damage (9, 12-13). Bacterial infection is closely linked to viral season, and there is strong
evidence that acute upper respiratory tract viral infections facilitate lower respiratory tract
bacterial colonization in CF patients (13). Viral infections, most commonly respiratory syncytial
virus (RSV) and influenza A/B, trigger exacerbations through recruitment of the inflammatory
response and associate with clinical deterioration and lung damage, resulting in decreased
pulmonary function (11, 13, 14).
The CFTR is widely expressed in the lungs and airways, most commonly in the cells of
the submucous glands, with lower expression in the surface epithelia (15). Hydration of the
epithelial mucosal layer is provided through an inwardly-directed Na+ conductance in response
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to CFTR-mediated outwardly-directed Cl' secretion (16). In CF lungs, hyper-absorption ofN a+
occurs due to the absence of the CFTR, which leads to further dehydration, mucus build-up and
eventual bacterial colonization (16 and reviewed in (17)).
I. A. ii. Pancreas
Pancreatic insufficiency (PI) develops within the first few years of life; 50% of one-yearolds with CF have PI, increasing to 85-90% by the time they reach 5 years of age ( 8, 18). PI is
characterized by the decrease or complete absence of pancreatic enzymes, namely amylase,
protease, lipase, phospholipase and colipase (19). The reduction in pancreatic function results in
malabsorption, symptomatically expressed as abdominal pain, steatorrhea, flatulence, diarrhea
and growth failure through vitamin A, D, E and K deficiencies (19). In consequence of these
deficiencies, patients must undergo PERT (pancreatic enzyme replacements for therapy), which
improves malabsorption, but does not correct the underlying problem (19). The CFTR is highly
expressed in the exocrine pancreas, primarily in the apical domain of the pancreatic duct cells
(20). It is responsible not only for the hydration of the mucosal layer, but acts also as a CFcoupled bicarbonate transporter to regulate the secretion of bicarbonate ions (HCO3') which
maintain the optimal basic pH necessary for pancreatic enzyme function (19, 21).
The loss of the CFTR affects the function of the pancreas in two manners. Firstly,
thickened mucus causes luminal obstructions and acinar cell destruction, which in turn causes
blockage of the ducts and fibrosis ( 8, 19, 22). Secondly, the loss of HCO3' alters the pH so
significantly as to cause precipitation of secreted proteins, thereby plugging the ducts (21). The
15% of patients who have residual pancreatic function, dubbed pancreatic sufficient (PS), still
suffer from impaired pancreatic ductal and acinar secretions when compared to the non-CF

4

population, however, they are more likely to have fewer symptoms, mild pulmonary disease and
an overall improved prognosis (18).
I. A. iii. Sweat Glands
Overly salty sweat is characteristically the first symptom o f CF for the majority of
patients (reviewed in (23)). A simple, pain-free diagnostic procedure known as the “sweat test”
measures chloride levels within the sweat of suspected individuals; sweat chloride levels > 60
mEq/L is considered abnormal and suggests a high likelihood of CF (24). The sweat gland is a
long tubule composed of two discrete areas with two separate functions; the secretory coil, which
secretes isotonic fluid in response to stimulation, and the H2O impermeable reabsorptive duct,
which reabsorbs ions in excess H2O (reviewed in (25)). The CFTR is found in the apical
membranes of both secretory coil and absorptive duct cells (26). To produce hypotonic sweat,
the CFTR pumps Cl' from the lumen into the duct cell, and through associations not fully
understood, also stimulates the epithelial sodium channel (ENaC) to reabsorb sodium into the
duct cell; both actions are contrary to CFTR roles in other organs (2, 27, 28 and reviewed in
(29)). The loss of CFTR prohibits CF reabsorption and ENaC function, which impede the
reabsorption o f sodium into the duct cells, resulting in high concentrations of NaCl within the
sweat of CF patients (24, 27).
I. A. iv. Liver
Liver disease, characterized by focal biliary cirrhosis and portal tract inflammation and
fibrosis, is prevalent in 4-30% of the CF population and is the second most common
complication of CF, next to pulmonary disease (8, 30-32). Hepatic disease usually appears in
childhood, with approximately 3-5% of children developing severe portal hypertension before
the age of 10 (31-33). CFTR is present in relatively low expression levels within the apical
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membrane of cholangiocytes, the epithelial cells which line the intrahepatic bile ducts (33, 34).
The CFTR is responsible for C f and HCO3' secretion into the lumen, which facilitates H2O
diffusion and the subsequent dilution and alkalinisation of bile fluid (27, 34). The lack o f CFTR
causes inspissated mucus which obstructs the ductules, stimulating a cholangiocyte-induced
inflammatory response resulting in cholangitis, focal biliary cirrhosis and portal tract fibrosis
(32, 33).
I. A. v. Reproductive tract
Over 95% of males with CF are infertile, the result of azoospermia caused by congenital
bilateral absence of the vas deferens (CBAVD) (36 and reviewed in (35)). Subsequently,
decrease in volume, increased acidity, and little to no fructose within the ejaculate have also been
documented and additionally affect male fertility (37). Azoospermia, a condition in which no
measurable level of sperm is found in the ejaculate, arises due to an anomaly in Wolffian duct
differentiation, which results in absent, atrophic or fibrotic vas deferens (36). The CFTR is
highly expressed in Sertoli cells during fetal development of the Wolffian ducts, where it is
responsible for maintaining an optimal fluid environment for the maturation, storage and
delivery of sperm (38). The loss of the CFTR has been implicated in the regression of the vas
deferens, an observation which is not fully understood. It has been speculated that fluid secretion
may play a vital role in proper development of the scrotal vas and distal epididymis (36, 39).
Females diagnosed with CF experience reduced fertility, though they show no obvious
anatomical abnormalities (38). There is much controversy as to the exact cause of this reduction,
but it is collectively accepted that female infertility in CF patients is multifactorial. CFTR is
expressed in endometrial epithelial cells lining the female reproductive tract, beginning in the
vagina and cervix, through the uterus and fallopian tubes (38). Its primary role was initially
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believed to be regulation of fluid secretions throughout the tissues, as thick, cervical mucus was
shown to be a barrier to sperm passage in CF patients (38). In recent years, researchers have
established that the CFTR is largely responsible for activation o f HCCV channels, an ion which
is crucial for maintaining optimal pH for sperm capacitation (38). In addition, it has been widely
assumed that reduction in fertility could also be due to delayed puberty and amenorrhea, the
result of malnutrition secondary to PI (40). Unlike males inflicted with CF, females can still
successfully reproduce, however it should be monitored as a moderate to high risk pregnancy
depending on the disease severity of the female (41).
I. A. vi. Gastrointestinal tract
The cells of the gastrointestinal tract (GI tract) that pertain to CF are illustrated in Figure
1.1. The GI tract has both secretive and absorptive functions, both of which are regulated by the
CFTR. Located apically in the epithelial cells lining the lumen, the CFTR is preferentially
expressed in the duodenum, with a decreasing gradient of expressivity observed through the
remaining portions of the GI tract (42). Histologically, CFTR expression is highest in the crypts,
with low levels of expression observed along the villus tips (42). The CFTR is responsible for
the balance of intestinal fluid by its regulation of C f at the basolateral and apical membranes
(43). The lack of CFTR, as seen in the case of CF, results in low luminal fluid, dehydration and
impaction of intestinal contents, and results in such manifestations as gastroesophageal reflux
disease (GEFD), ileocolic intussusceptions, appendicitis, rectal prolapse, fibrosing colonopathy
and an increase in susceptibility to Crohn’s Disease (43, 44 and reviewed in (45)). Meconium
ileus and distal intestinal obstruction syndrome are two common complications of CF and are
reviewed in more detail below.
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Intestinal
Villus

Figure 1.1. Absorptive and Secretive Cells of the Intestinal Epithelium. Enterocytes (taupe)
found in the villus function primarily as absoiptive cells. Enterocytes found in the crypts,
otherwise known as gland enterocytes (pink), have secretory functions. Goblet cells (blue)
produce and secrete mucus.
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I. A. vi. 1. Meconium ileus
Meconium ileus (MI) occurs in 10-20% o f newborns with CF. It is frequently the first
manifestation o f CF and has been linked with PI, high morbidity and early death (47-49). MI is
the obstruction o f the ileum by meconium, a mixture o f mucus, lanugo, amniotic fluid, bile and
water which composes a newborn’s first bowel movement (10, 50). Complications o f MI include
perforation, volvulus, small bowel atresia, and meconium peritonitis with abdominal
calcifications, resulting in death if left untreated (50). Improved management o f the disease has
drastically reduced deaths and MI patients can be expected to have a similar outcome to those
not inflicted with the childhood disease (reviewed in (46)).

I. A. vi. 2. Distal intestinal obstruction syndrome
Distal intestinal obstruction syndrome (DIOS) is largely considered to be the adult
equivalent o f MI, however, the two have very different etiologies. Patients often complain of
recurrent lower right quadrant pain, abdominal distension and vomiting secondary to bowel
obstruction (51). DIOS presents as partial or complete obstruction o f the terminal ileum by
viscous intestinal secretions and undigested food, and is considered a secondary symptom to PI;
the addition o f pancreatic enzymes alleviates symptoms and reduces occurrence (45, 52).
Estimates o f DIOS vary greatly, from 2-40% o f adolescent and adult patients, many o f whom
present later in life (8,47).

I. B. Cystic fibrosis Transmembrane Conductance Regulator
I. B. i. CFTR gene
CF is caused by mutations in the gene encoding the CF Transmembrane Conductance
Regulator (CFTR) (3). It is located on the long arm o f chromosome 7 at position q31.2, is 250 kb
long and consists o f 27 exons (3).
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I. B. ii. Structure of CFTR
The CFTR is a member o f the ATP-Binding Cassette (ABC) transporter super family.
Unlike the rest o f the family, the CFTR functions as a cAMP-activated chloride channel (2, 5,
27). It is comprised o f a single polypeptide o f 1480 amino acids, which folds into five domains:
two transmembrane regions (TMD), two nucleotide-binding domains (NBD) and a hydrophilic
regulatory domain (R domain) which has many phosphorylation sites for protein kinase C (PKC)
and protein kinase A (PKA) (1 ,2 , 5). As shown in Figure 1.2, the CFTR forms two symmetrical
halves, with each half containing a membrane spanning region composed o f six a-helices and an
intracellular NBD region which contains conserved Walker A (GXXGXGKT/S) and Walker B
(R/KX7- 8h4D) motifs required for ATP binding and hydrolysis (1, 2, 5). Which regions are in
direct contact with each other has not been elucidated, however it is widely believed the
membrane spanning regions form the pore o f the channel (53, 54).

I. B. iii. Function of CFTR
As mentioned above, the CFTR is a cAMP-activated chloride channel. A G-protein
coupled receptor is activated through binding o f a ligand, which stimulates adenyl cyclase to
convert ATP to cAMP, a second messenger activator o f PKA. Upon phosphorylation o f key
residues on the R domain by PKA, the channel partially opens to reveal NBD1 and its Walker A
and Walker B motifs for ATP binding (2). After NBD1 binds and hydrolyzes ATP, the channel
opens to allow the flow o f anions through the pore, but the stability o f the open conformation
requires additional phosphorylation on the R domain to reveal NBD2 (2 and reviewed in (5)).
NBD2 binds ATP, stabilizing and sustaining the open conformation for longer periods, upon
which ATP hydrolysis closes the channel (Figure 1.3) (2). The channel can fluctuate between
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CFTR
TMDl

TMD2

Out

In

Figure 1.2. Structural Prediction of the CFTR. The CFTR is composed of 1480 amino acids
which fold into five domains: two transmembrane domains (TMD) of six helical structures each,
making the pore; two nucleotide-binding domains (NBD). which hydrolyze ATP; and a
regulatory domain (R domain) which opens and closes in response to PKA phosphorylation.
Adapted from Vankeerberghen et al (2) and Bompadre et al (1).
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The CFTR shows a high selectivity for anions over cations, with a permeability
preference of Br"> C f> I‘> F' (2). It has also been shown to have permeability to polyatomic
anions, preferentially to NC>3'> C f > HC0 3 > HCOCT > CH3CO2" (55). Extracellular C f is
taken up basolaterally into the cell through the Na+K~2Cf co-transporter (NKCC), and then
secreted into the luminal compartment by the CFTR (1 and reviewed in (29)). The outwardlydirected C f conductance creates a negative potential, which drives passive Na+ diffusion and
water into the lumen, thereby creating a small conductance of 7-10 picosiemens (pS) and a
balance between absorption and secretion (2 and reviewed in (29)).
There are several defects in epithelial cell functions which cannot be solely explained by
loss of C f conductance. The CFTR has been implicated as being a regulator, either directly or
indirectly through protein-protein interactions, of several epithelial cell channels including the
ENaC, renal outer medullary potassium channel (ROMK) and other outw ardly rectifying C f
channels (ORCC) (1, 27 and reviewed in (29)). Of particular importance, research has shown
that the ENaC is functionally coupled and influenced by the CFTR (27). Upon stimulation with
cAMP, the CFTR represses Na+ absorption from the lumen of normal tissues, however, this
repression is lost in CF patients and hyperabsorption of Na+ leading to further dehydration is
observed (16, 27). In contradiction to these findings, the ENaC is stimulated by the CFTR to
reabsorb Na+ in the sweat glands (27). How these two proteins interact under these conditions is
still a mystery.
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Figure 1.3. Model of CFTR Gating. Partial phosphorylation by PKA allows NBD1 (white) to
bind and hydrolyze ATP. briefly opening the channel. Complete phosphorylation allows NBD2
(purple) to bind ATP. stabilizing the open conformation. Hydrolysis at NBD2. and the release of
ADP and Pi at both sites, closes the channel. As long as the R domain remains fully
phosphorylated. many cycles of ATP binding and hydrolysis, and subsequent opening and
closing of the channel, may occur. Dephosphorylation of the R domain closes the channel
indefinitely until PKA phosphorylation occurs once again. Modified from Bompadre et al ( 1).
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I. B. iv. Mutations of CFTR
According to the most recent estimates by The Human Gene Mutation Database®, there
are 1489 mutations documented within the CFTR gene (4). Mutations may be present throughout
the gene and promoter region, and are categorized as frameshift mutations, missense mutations,
nonsense mutations, insertions or deletions (8). The AF508 mutation is caused by a three base
pair deletion that results in the loss of a phenylalanine residue at position 508 o f the NBD1, and
accounts for over 70% o f CF mutations in the Caucasian population (6). While an additional 10
15 mutations appear in approximately 1-5% o f patients, the vast majority o f CFTR mutations Eire
quite rare (8 and reviewed in (7)).
CFTR mutations can be grouped according to their biochemical effects on the protein.
Class I mutations are most often nonsense mutations or insertions/deletions, which cause altered
splicing, resulting in premature stop signals and defective protein synthesis (8). The majority of
mutations, including AF508, are Class II mutations, which cause altered processing and
degradation o f the CFTR in the ER. Class III mutations affect the efficiency o f the R domain by
limiting its response to cAMP stimulation. Class IV mutations are often missense mutations and
are found in the transmembrane regions o f the protein. They affect ionic conductance by
reducing the length o f time of channel opening. Class V mutations result in decreased synthesis
o f a functional CFTR protein. Class VI mutations truncate the C-terminus, decreasing the
stability o f the CFTR and resulting in degradation (8,23).

CF is a haplosufficient single gene disorder; mild mutations have a dominant effect and
can compensate for a severe mutation (8). Class I, II, and VI mutations are severe, in that no or
very little functional CFTR reaches the apical membrane. Class III, IV and V mutations are often
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mild, as some residual function remains. Some mutations are more pronounced in certain organs;
AF508 correlates with a severe lung and pancreatic phenotype, yet shows weak correlation with
intestinal severity (7, 47). Taken together, the size and mutational heterogeneity of the CFTR
gene present as a complex problem.
I. B. v. CFTR expression in humans
Previously, studies using in situ hybridization with a cRNA probe have been performed
to assess CFTR levels throughout thé human GI tract (42). CFTR is diffuse and expressed at low
levels in the stomach, but the duodenum shows relatively high expression. Expression decreases
through progression into the intestinal tract, with the colon showing the lowest CFTR expression.
Similarities exist between the duodenum and jejunum and between the ileum and colon with
respect to which cell types express CFTR and where they are located. CFTR mRNA is highly
expressed in the crypts, with a decreasing gradient of expression through the villus tips.

I. B. vi. CFTR expression in rats
Previously, studies have been undertaken to assess Cftr expression in the rat GI tract (56).
Similar to the studies performed in humans, in situ hybridization experiments were performed,
using a cRNA probe, throughout the stomach, duodenum, jejunum, ileum and colon of rats. Cftr
expression was highest in the crypts and lowest in the villus tips, akin to the expression pattern in
humans. Again, Cftr expression is highest in the duodenum, with a decrease in expression along
the distal axis through the GI tract.
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I. C. Cystic fibrosis mouse models
Two years after isolation of the CFTR by Riordan et al (3), the murine Cftr gene was
identified (reviewed in (57)). It is located on chromosome 6, spans approximately 152 kb and
contains 27 exons (58). The CFTR and Cftr proteins are 78% identical at the amino acid level,
including a phenylalanine residue at position 508 and, unexpectedly, this high degree of
conservation between the two species applies to the introns as well (58). In situ hybridization
studies have shown that Cftr is highly expressed throughout the GI tract, with lower expression
in the stomach, esophagus, lung, liver, genitourinary tract and pancreas (42, 58-59 and reviewed
in (57)).
There are several different methods that have been employed in constructing CF mouse
models, each with their own distinct characteristics (Table 1.1). Specific mutations replicating
those found in humans have been made through gene replacement or double homologous
recombination (reviewed in (57)). More commonly, Cftr disruption can be achieved through gene
replacement or insertions, which result in null mutations and some residual activity (10%),
respectively (reviewed in (57)). One of the most popular strains is the S489X, which carries the
CftjpnH/NC mutatjon (go). A targeted insertion of a neomycin gene into exon 10 creates a
premature stop codon, effectively truncating the protein and recreating the AF508 defect seen in
CF patients (59, 61). Given the similarity, it was expected that a murine CF model would exhibit
the classical manifestations of the disease, but this has shown to only partially be true.
CF mouse models maintain a Mendelian ratio o f 1:2:1 for CFTR +/+, CFTR +/- and
CFTR -/-, respectively (59). Homozygous knockouts (-/-) appear smaller than their wild-type
(+/+) counterparts, and develop the characteristic failure to thrive phenotype common in CF
patients (59, 62). Intestinal disease is the first and most severe manifestation of CF in the murine
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models and appears at birth or at the time of weaning (21 days) (reviewed in (57)). Symptoms
include goblet cell hyperplasia, mucin accumulation, crypt dilation, intestinal obstruction,
perforation, peritonitis and eventually death (63). Additionally, the cecum becomes coiled and
impacted with fecal material, not unlike the appendix, and perforations can lead to healed
ruptures linking sections of intestine together, which exacerbates abdominal obstruction (59).
Other organs are affected in the mouse model, though not as detrimentally as the GI tract.
Cftr is highly expressed throughout the genitourinary tract of both males and females, but in
contrast to CF patients, males have reduced fertility whereas females are completely infertile
(reviewed in (57)). It has been noted that the CftiJmIUNC mice have abnormal pigmentation of
their incisors, a decrease in enamel and an increase in mineral composition, leading to high
incidence of fracturing and premature wear (65, 66). CF mice do not show any pancreatic
deficiency, which could be attributable to alternative chloride channels, and ultimately limits the
utility of mouse models for pancreatic CF research (58). Most surprising, lung disease is not the
primary cause o f death, nor is it present in all strains of mouse models, a phenomenon that is
further discussed below.
I. C. i. C57BL/6 CF mice
It was initially believed that CFTR 7- mice do not develop lung disease, making them
poor models of CF. It was noted, however, that two key measures were not taken into
consideration during early research; the requirement of a non-sterile environment to procure
infections and thus chronic inflammation, and a sufficient amount of time, possibly years, for
these events to unfold (reviewed in (57)). Another observation has also been documented in
which not all strains are equally characteristic of the disease and that some are more prone to
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Strain

Mutation

(C57BL/6/129
BALB/cJ/129)

Exon 10
Replacement

Cfttrm,Hgu
(MF1/129)

Exon 10 Insertion

CftipnlCam
(MF1/129
C57BL/6/129)

Exon 10
replacement

CftifmIHsc
(CD 1/129)

Exon 1
Replacement

Death by Ileal
Obstruction
50% by day 7
40% by day 21
<5% reach
maturity
5% by day 7
2% by day 21
90% reach
maturity
80% by day 7
10% by day 21
<5% reach
maturity
55% by day 7
20% by day 21
25% reach
maturity

Body Weight

Reference

10-50% reduction

59

No reduction

64

50% reduction

106

Delayed

72

Table 1.1. Summation of four CF mouse models and their characteristics. The original
mouse strain, CFTR mutation, morbidity and body weight relative to unaffected wild-type
littermate are summarized for the following CF mouse models: CftrlmWnc, Cftr‘mIHgu, Cfti,mlCam,
C ftrmIHsc. Adapted from Davidson et al (57).
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lung disease than others (67). Specifically, the c ftr mIUNC C57BL/6 congenic strain of mouse
(herein referred to as UNC B6) does develop lung disease and has one of the lowest survival
rates after weaning (<5%) of all CF mouse models (61, 67-69). Symptoms present at 4 weeks of
age, with an increased influx of neutrophils preceding the first lesions (69). At 6 months of age,
inflammation can be seen, along with thickened alveolar walls and alveolar hyperinflation,
interstitial fibrosis, bronchiolar mucus retention and a decrease in non-ciliated cells (69). Not
surprisingly, UNC B6 mice are highly susceptible to infections with CF associated pathogens,
which coincide with the timing of the amplified inflammatory response (69). Though the
distribution of submucosal glands differ between human and mouse respiratory tracts (58), the
same increase in Na+ basal rate absorption is seen between the UNC B6 and CF patients, which
fortifies the rationale for the use of these mice in modelling CF (70).
I. C. ii. BALB/cJ CF mice
Cftrtm,uNc BALB/cJ mice (herein referred to as UNC BC) do not develop the lung
phenotype that the UNC B6 mice do (67-69, 71). A perpetual influx of neutrophils can be seen
beginning around 5 weeks of age; however, the disease progresses no further, and fibrosis and
mucus retention do not occur (68). Comparing the genomes of the two strains, researchers were
able to determine specific genes which could be responsible for the contrast in phenotypes.
These included genes involved in lymphocyte activation, immune cell response, cellular
proliferation, transcription regulation and intracellular signalling (68). Though studies are still
inconclusive, it is believed certain genes are silenced in the UNC BC mice, and thus do not
amplify the inflammatory response as seen in the UNC B6 strain (69).
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I. D. Modifier genes and Cystic fibrosis
I. D. i. Genetic modifiers in CF mice
Previously, a CF mouse founded in the 129/Sv strain was created by the insertion of a
neomycin resistance cassette into exon 1 o f the Cftr, herein referred to as Cftr

(72). This

insertion caused a disruption of exon 1, resulting in a complete knockout of the gene product.
The resulting progeny were bred with CD1 females, resulting in unaffected heterozygous FI
hybrids, which were subsequently intercrossed to generate Cftrm,HSC/Cftrm,HSC mice (F2). Many
of these F2 mice had severe intestinal obstruction, resulting in death shortly after birth or at the
time o f weaning. A significant (30%) number survived beyond 6 weeks of age (72). Based on
these findings, three classes of mice emerged. Class I and II mice die within 10 days of birth and
at the time o f weaning, respectively, due to severe intestinal obstruction. Class III mice exhibit a
mild to absent phenotype and have no shortened lifespan (Figure 1.4) (72).
The prolonged lifespan of the Class III mice was assumed to be due to an unlinked
modifier locus not present in the Class I and II mice. To determine if this was true, male F2 mice
from Class III were backcrossed to female heterozygous FI progeny, resulting in a larger
percentage of offspring surviving past 6 weeks of age (72). Strain specific differences were noted
when the 129/Sv founder line was crossed with the different inbred mouse lines ofC57BL/6
(B6), BALB/cJ (BC) and DBA/2J. Survival rates varied, from 24% to 31% for B6 and BC after 6
weeks o f age, to only 8% one week after birth for the DBA/2J (72). Genetic linkage analysis
using a genome scan with polymorphic DNA markers mapped a modifier locus at D7Mit56 of
chromosome 7, which is associated with the CD1 strain (72). In fact, analysis of Class I - III
showed segregation of the CD1 locus with Class III, where as Class I and II favoured 129/Sv at
that locus.

Age (weeks)

Figure 1.4. Mortality of Cftr'"1Hsc CF mice. Age and associated survival in Cftrm,Hs7 Cftr'm,Hsc
mice (72). Mice showed prolonged survival when backcrossed with different inbred strains
(C57BL/6, BALB/cJ and DBA/2J). Mice were classed based on their suspected mortality due to
intestinal obstruction. Class I mice die within 10 days after birth, Class II mice die at the time of
weaning (21 days) and Class III mice survive into maturity (>6 weeks of age).
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I. D. ii. Genetic modifiers in CF patients
Despite being a monogenic disease, not all cases of CF present identically with respect to
age of presentation, symptoms and prognosis. This has been partially explained by the different
biochemical effects each mutation has on CFTR function. As previously noted, there have been
over 1400 mutations documented within the CFTR gene; however, CF patients carrying the same
mutated alleles do not necessarily present with the same symptoms or severity of disease
expression (23, 47, 73 and reviewed in (75)). In addition, certain organs within the same
individual may present with varying degrees of severity, and the presence or absence of severe
alleles alone is not enough to explain the discrepancy (23, 76). This has led many to believe that
CF is modulated by other factors outside of the CFTR genotype, and environmental and/or
genetic determinants could be strong influences of disease progression (8, 47, 48, 76, 77).
MI only occurs in those with PI, is more frequently found associated with the AF508
mutation (79% vs 68% non-MI), and has a familial recurrence rate of 80% (47, 78). Studies of
mono- and dizygous twins carrying a homozygous AF508 mutation have shown a higher
concordance between clinical phenotype in monozygous than dizygous twins, suggesting genetic
factors are largely responsible for clinical presentation (76, 79). In fact, some have postulated
that MI is present in all CF patients, but some patients have common genetic factors which
protect against its manifestation (47). Association studies and linkage analysis have uncovered
several potential modifier gene loci, including 8p23.1, 1 lq25, 20pl 1.22, 21q22.3, 4q35.1 and
19ql3. 19ql3 has been determined as a putative modulator of MI and therefore known as the CF
modifier 1 locus (CFM1), and is the conserved synteny to D7MH56 previously described in the
mouse (47, 72). It has long been suspected that modifiers could be related to alternative Ca2+activated C f channels, as these channels have been found in murine lung, pancreas and intestinal
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tract of long-living CF mice, the organs which show the mildest disease phenotype (23, 72, 73,
76). Recently, association studies have shown the chloride channel, calcium activated (CLCA)
locus on chromosome 1 to be linked to residual CF conductance in the intestinal tract of CF
patients (73).
I. E. CLCA family of proteins
I. E. i. CLCA gene family
Approximately 20% of homozygous AF508 CF patients have residual CF conductance in
the absence o f functional CFTR, and this phenomenon was also seen in the small intestine of a
murine CF model (73, 80-83). These CF currents are induced by intracellular Ca2+-mobilizing
agents, can be blocked by the anion exchange inhibitor 4,4’-diiso-thiocyanostilbene-2,2’disulfonic acid (DEDS) and show concordance with prolonged survival (81, 84, 85). The CLCA
family of proteins is well-conserved among mammals, spanning at least eight known species
(human, mouse, rat, horse, cow, pig, canine and chicken) and consisting of over 20 members (82,
83-92). Though diverse, each member shares key features indicative of the family. The majority
are type 1 transmembrane proteins of 902-943 amino acids, with a symmetrical cysteine motif at
the amino terminus, and 4-5 putative transmembrane domains (82, 86, 87, 94, 95). Consistent
with a Ca2+-activated/dependent protein, each member has numerous phosphorylation sites for
calmodulin kinase II (CaMKII) and protein kinase C (PKC), which regulate channel activity
through Ca2+-dependent phosphorylation of key residues (86, 96). After glycosylation, which
stabilizes the protein and prevents premature degradation, the 110 kDa protein undergoes
proteolytic cleavage at a lysine near residue 680, separating the protein into a 90 kDa N-terminus
and a 35 kDa C-terminus (86, 94 and reviewed in (97)). The two halves remain associated
together at the plasma membrane, though the mechanics of this is still unknown (86, 87). It is
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important to note that the above is a structural generalization of the family, as exceptions to the
rule are common. It is still unclear what function CLCA proteins have, since members have been
implicated as adhesion molecules, tumour suppressors, putative ion channels, channel regulators,
promoters of protease activity and apoptosis and soluble signalling molecules (86, 87).
The first CLCA family member was isolated from bovine tracheal epithelium in 1995
(88). It was later found to confer a conductance of 25 pS after CaMKII activation, with ion
selectivity similar to the CFTR (96). Structural data verified that bovine CLCA1 (bCLCAl)
contained four transmembrane regions, several consensus sites for N-linked glycosylation and
the presence of phosphorylation sites for CaMKII and PKC (96). Concurrently, bCLCA2 was
identified in pulmonary venous endothelium, and though it lacked any current activity, it did
show adhesion properties and the ability to interact with integrin P4 (95, 98 and reviewed in
(97)). Since then, additional CLCA family members have been identified in pigs, rats, dogs,
horses, chickens, humans and mice. Not much is known yet about CLCA proteins in other
species, however, porcine CLCA1 (pCLCAl) and equine CLCA1 (eCLCAl) are orthologs and
solely found in goblet cells, where they could interact or regulate mucin (80, 99).
I. E. ii. Human CLCA genes
Using bCLCAl/2 as probes, four human orthologs were identified that clustered together
on chromosome lp22-31 (73, 89). Human CLCA1 (hCLCAl) is the human ortholog of pCLCAl
and eCLCAl, and is found throughout the GI tract in goblet cells and basal crypt epithelia (73,
80, 89, 99). Much like bCLCAl, it does confer a Ca2+-activated C f current when stimulated (95).
Due to its over-expression in asthma, it has been implicated in mucin overproduction and goblet
cell hyperplasia (84, 100). Though its role in CF has yet to be elucidated, hCLCAl does interact
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with the CFTR, and is the likely candidate of Cl' conductance from the CLCA locus (101).
hCLCA2 is found in mammary tissue, kidney, lung and trachea endothelium (80, 86, 96, 101).
Though it has been shown to induce C f current, it has been implicated as an adhesion molecule
for its integrin 04 sites (a receptor responsible for linking cytoskeletal and extracellular matrix
proteins together), though this is still a subject of much debate (95). Specifically, its downregulation in breast cancer has led many to believe it to be a detachment-inducible, tumour
suppressor gene (86). hCLCA3 is unique among CLCA family members. Not only is it truncated
at 37 kDa (compared to the standard 110 kDa size for the other members), but it is also the only
member shown to be secreted and not membrane bound (96). It has been localized to lung,
trachea, spleen, thymus and mammary gland; its function is of yet unknown (96). hCLCA4 is
localized close to hCLCAl on the CLCA locus, and has also been thought of as a potential
candidate of C f conductance (73). It is highly expressed in the brain, unique for CLCA
members, and in the uterus, testis, appendix, trachea, bladder, prostate, salivary glands,
mammary glands and throughout the GI tract (73, 84, 87, 96 and reviewed in (97), (102)). Its
function, much like the rest of the CLCA family members, is unknown.
I. E. iii. Murine CLCA genes
To date, six murine CLCA members have been identified on chromosome 3 (band H2H3) between D3Mitl97-D3Mit261, and a seventh member is postulated to have been located
(87, 95, 99, 101 and reviewed in (97)). Mouse CLCA1 (mCLCAl) and mCLCA2 are 96%
identical at the mRNA level, and 92% identical at the amino acid level, leading many to believe
that mCLCA2 is a splice variant of mCLCAl (91). Both proteins are found in the intestinal
crypts and in mammary tissue, and both share adhesion properties (87, 95). mCLCA3, aka Gob5, is the murine ortholog to hCLCAl, and is similarly found in goblet cells throughout the GI
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tract and in the lungs (62, 84, 92, 99). It encodes a 110 kDa glycosylated protein, which quickly
undergoes cleavage in the ER into 80 kDa N-terminal and 35 kDa C-terminal fragments (94, 99).
Computer algorithms have predicted a von Willebrand factor, type A (VWA) domain and a
fibronectin type III (Fnlll) domain, found in extracellular matrix proteins and cell surface
binding proteins, respectively (103-105). Due to the fact that mCLCA3 lacks any transmembrane
domains, it is hypothesized that mCLCA3 is in fact a soluble, secreted protein (99, 103, 106).
mCLCA4 is the most highly expressed CLCA protein in the GI tract (84). It is found within
smooth muscle cells, and similar to many other members, it does confer a Cl' conductance upon
Ca2+ stimulation (82, 84, 95). mCLCA5 is the murine ortholog to hCLCA2, and has the most
extensive tissue expression profile of any murine member, being located in the endothelium of
the esophagus, GI tract, pancreas, kidney, lung, uterus, spleen, heart, aorta, mammary gland and
eye (80, 86, 95). mCLCA6 is the most recently discovered of the murine CLCA proteins, and is
the murine ortholog of hCLCA4 (87, 95). It is glycosylated and cleaved into a 110 kDa Nterminal fragment and a 35 kDa C-terminal fragment, which associate at the plasma membrane
through as o f yet unknown interactions (87). mCLCA6 is highly expressed in the GI tract,
second only to mCLCA4, and is located in the villous tips of non-goblet enterocytes in the small
intestine, and within the crypts of the colon. O f special note, confocal laser microscopy has
verified that mCLCA6 does co-localize with the CFTR in the large intestine (87). Figure 1.5
highlights the similarities and differences between the murine CLCA family members.
I. E. iv. Role of mCLCA3 in Cystic fibrosis
mCLCA3 has been hypothesized to be involved in the synthesis, condensation and
secretion of mucins, largely due to its increased expression in murine asthma models and the
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Figure 1.5. Proposed structural domains of murine CLCA family members. A. A
dendogram showing family member origin based on known amino acid sequences, modified
from Huan et al (100). B. Proposed protein structures of all six known mCLCA family members.
Molecular weights are given for post-translationally modified proteins. Anticipated cleavage
sites are given, separating the N-terminus (white) from the C-terminus (blue). Shown are
approximated N-linked glycosylation sites (light blue), the conserved cysteine sequence C-12XC-4X-C-4X-C-12X-C (yellow), transmembrane domains (green), von Willebrand factor, type A
(purple), fibronectin III domain (orange). (34 integrin binding sites (black triangle) and consensus
phosphorylation sites for PKC/CAMKI1 (red).

27
observed mucin overproduction and goblet cell hyperplasia in these models (84,100,106).
Leverkoehne et al (84) found that the severely affected CftrlmlCam mouse model (with a
deleterious insertion into exon 10) had elevated mCLCA3 expression, whereas the
CjfrTgH(neoim>lHgu mouse model (also with an exon 10 insertion), with reduced mCLCA3
expression, presented with a milder phenotype (107). In contrast, some CF mouse models, such
as CftrlmIUNC, have shown severe phenotypes correlating with decreased mCLCA3 expression,
discrepancies not yet fully understood (94). Regardless o f the conflicting data, it is apparent that
mCLCA3 has an important role with respect to CF mouse intestinal disease.
Previous research in Dr. Rozmahel’s laboratory studied differential gene expression
among juvenile congenic UNC B6 and UNC BC WT and CF mice to identify genes that may
contribute to the distinct CF-associated lung phenotypes among the different mice. Using
Affymetrix GeneChip technology, genes showing a difference in expression in excess o f 2-fold
were considered significant. O f the 31 (from >18,000) most promising genes meeting the
stringent criteria, and confirmed to be differentially expressed by Northern blot or quantitative
RT-PCR analysis, one was identified as mClca3 (108). The mClca3 mRNA was significantly
over-expressed in UNC BC, but not UNC B6, CF mouse lung compared to WT, as seen in Figure
1.6a. Northern blot studies confirmed that 1) mClca3 was expressed in lung tissue o f mice, 2) its
expression was dramatically elevated in the lungs o f UNC BC CF compared to WT mice, and 3)
the gene product had markedly reduced expression (detected only at low levels) in the severe
UNC B6 CF mouse lungs (Figure 1.6b) (109).
Based on these findings, an UNC B6 transgenic mouse line was constructed using the rat
intestinal fatty-acid binding promoter (rIFABP) element, to determine if up-regulation o f mClca3
correlated with improved survival. Transgenic CF mice weighed as much as their WT
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showed diminished mucus production and obstruction throughout the GI tract and experienced a
normal, unaffected lifespan (62). In summary, the increase in mClca3 expression ameliorated CF
intestinal disease.
I. F. Thesis Introduction
It has been previously shown that severity of intestinal lesions and subsequent time of
death varies among different genetic backgrounds o f mice with CF (47, 67, 72, 110, 111). For
instance, CFTR knockout mice on the congenic UNC B6 background present with a severe
intestinal phenotype due to ileal obstruction, leading to premature death soon after birth or at the
time of weaning (59). In addition, the strain also develops a lung phenotype at 5 weeks of age
similar to CF patients (68, 69). Mice from the UNC BC strain also develop a severe intestinal
phenotype, however, a larger percentage reach adulthood (59, 68, 72, 112). In contrast to UNC
B6, UNC BC mice do not develop lung disease (67). These results, in addition to the
overwhelming data reported elsewhere, have indicated a role for secondary genetic factors as
modifiers of CF disease severity in the mouse.
The CLCA family of proteins have a role in mediating Ca2+-activated C f conductance in
CF patients and CFTR knockout mice, either directly as a putative CF channel, or through
protein-protein signalling interactions (80, 82, 92, 95, 96, 109). Additionally, some members
have been implicated as having functions related to mucus synthesis, condensation and secretion
(84, 99, 106). Specifically, mCLCA3 has been established as a soluble, secreted protein with
proposed involvement in the mucus regulation of asthma and CF (62, 92, 94, 99, 103, 113). In
the severely affected UNC B6 mouse model, mCLCA3 shows decreased expression throughout
the GI tract (109). A transgenic CF mouse line over-expressing mCLCA3 was found to show
amelioration of CF intestinal symptoms (62).
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Figure 1.6. Differential expression of mCLCA3 in UNC B6 and UNC BC CF whole lung. A.
Semi-quantitative RT-PCR. C57BL/6 CF mice show reduced expression of mCLCA3 compared
to their WT counterparts in a study by Chung et al (109). BALB/cJ CF mice show grossly
increased expression of mCLCA3 compared to their WT counterparts. mCLCA3 expression was
normalized to G3PDH. B. Northern blot of mCLCA3 expression in lung. Transcriptional levels
of mCLCA3 are shown for males and females of both strains. WT levels are undetectable for
both C57BL/6 and BALB/cJ mice. BALB/c.l CF mice show higher expression of mCLCA3 than
C57BL/6 CF mice. G3PDH was used as a loading control.
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Due to the recent establishment of mCLCA3 as a potential genetic modifier of CF, the other
CLCA family members have gained considerable interest. mCLCA4 and mCLCA6 are both
widely expressed in the GI tract, but little is known of their function. More recent studies have
shown that both could potentiate a CF current, and mCLCA6 has been co-localized with the
CFTR in the crypts of the large intestine, though the significance of this finding is hotly debated
(82, 87, 95).
Given the expression pattern and subsequent pathological significance of mCLCA3,1
hypothesize that differential CLCA expression between WT and CF ileal tissue implies a role in
intestinal disease severity in UNC B6 mice. Currently, minimal knowledge of other CLCA
family members exists, thus the primary purpose of this thesis is to determine if differences exist
in mClca4 and mClca6 mRNA expression between a WT and CF mouse model. In addition, this
thesis intends to investigate mClca expression patterns in the mouse model, and what effect age
and strain may have on these patterns. Given the co-localization of mCLCA6 with the CFTR,
this study also characterizes the expression of Cftr transcripts throughout the GI tract of mice, as
quantitative mRNA data is lacking. It is the intention of this thesis that these results may support
a complementary role for the two chloride channels in mouse CF intestinal severity.
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II.

Materials and methods

II. A. Mouse Studies
II. A. i. Animal Sources and Husbandry
Prior to the research in this thesis , the mixed background C57BL/6
Cftr('mimc)/Cf tr(’miuNC) a n d

B A L B /C J

Cf tr<>miuNC)/Cj-tr(tmiuNC) m i c e were created at the University

of North Carolina (59) and were bred to congenicity by Dr. Geraldine Kent at the Hospital for
Sick Children, Toronto, ON (71). Dr. Kent provided both congenic C57BL/6 (UNC B6) and
BALB/cJ (UNC BC) mice and breeding colonies were established at the Victoria Research Labs
vivarium in London, ON. All mouse studies were approved by the Animal Use Committee at the
University o f Western Ontario and followed the guidelines of the Canadian Council on Animal
Care. All animals were maintained on either a congenic B6 or BC genetic background. All mice
were housed in either shoebox or colony cages in a conventional facility. Pups were weaned, ear
notched and tail clipped between 18-20 days of age and analysed for genotype. Mice identified
as Cftr+I+and Cftr+I~were weaned and maintained on a regular chow diet at 21 days o f age. Mice
identified as C ftr1' were weaned and maintained on a special liquid diet at 21 days of age. One
250 mL can of liquid Peptamen (Nestle, North York, ON) is composed of protein (10 g), fat (9.8
g), carbohydrates (32 g) and water (212 g), amounting to 250 calories. All studies described were
performed on congenic B6 or BC mice so as to eliminate the possibility of secondary genetic
contributions to the phenotype.

II. A. ii. Genotyping
Genomic DNA was prepared from tail clippings using a salting-out extraction procedure
(114). In brief, 1 cm of tail was removed and digested overnight at 55°C with proteinase K (0.5
mg/ml). The protein pellet was then precipitated with a 5 M NaCl solution followed by
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centrifugation (Centrifuge 5417C, Eppendorf) at 13,000 rpm for 20 minutes. DNA was
precipitated through centrifugation after an addition of isopropanol and later ethanol. The DNA
pellet was dissolved in Tris-EDTA buffer (pH 8.0). To identify Cftr(tmIUNC> mutant mice
(designated CF mice herein), PCR reactions were performed as previously described58. Wild
type (WT) and mutant (CF) Cftr alleles were detected by PCR, using primers specific for the
endogenous Cftr locus and mutant locus: 03215 UNC (WT) 5'CTGTAGTTGGCAAGCTTTGAC-3' (Sigma-Genosys, Oakville, ON); NE045 UNC (CF) 5'ACACTGCTCGAGGGCTAGCCTCTTC-3' (Sigma-Genosys, Oakville, ON); CF67 UNC (WT
and CF) 5'-CAGTGAAGCTGAGACTGTGAGCTT-3' (Sigma-Genosys, Oakville, ON). The
PCR was performed using standardized conditions: 2 mM MgCE, 2 mM dNTPs, 50 ng/pl
primers, 100 ng genomic DNA and 1U Taq polymerase. Thermal cycling was carried out for 35
cycles (30 seconds at 94°C, 45 seconds at 64°C, 60 seconds at 72°C, followed by a 7 minute
extension at 72°C) using the GeneAmp® PCR System 9700 (Perkin Elmer, Montreal Quebec).
After electrophoresis the PCR products were visualized on an ethidium bromide stained 1%
agarose gel.

II. A. iii. Tissue Isolation
Mice were considered juvenile (3-4 weeks of age) or adult (>6 weeks). All mice were
sacrificed by cervical dislocation, as outlined by the Canadian Council on Animal Care. The
stomach, small intestine and colon from UNC B6 mice (10 mice/age/genotype) were harvested.
The small intestine was dissected by cutting it adjacent to the stomach, and then cutting adjacent
to the cecum. The whole portion of small intestine was flushed using lx PBS solution to remove
all fecal particulate. The duodenum was grossly approximated by removing 1 cm of the most
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proximal portion of the small intestine. The ileum was grossly approximated by removing 1 cm
of the small intestine adjacent to the cecum. The jejunum was grossly approximated by removing
a 1 cm portion of the small intestine equidistant from the proximal and distal ends. The colon
was grossly approximated by removing 1 cm of the most distal portion of the large intestine.
Similarly, ilea from juvenile WT and CF UNC BC mice (7 each) were also harvested. In
addition, the lungs, brain, liver, kidney, spleen, colon, heart, uterus, stomach and ileum from one
juvenile WT UNC B6 mouse were harvested. Samples were preserved in RNAlater™ RNA
Stabilization Solution for Tissue (Sigma) and stored at -80°C. For histochemistry, ileal sections
were collected from each strain at each age point and genotype and preserved in 10% formalin.

II. B. m Clca RNA expression
II. B. i. Isolation of RNA and reverse transcription
Total RNA was isolated and purified using a silica gel-based membrane as per protocol
outlined in the RNeasy Mini Handbook Third Edition (pages 50-55; Qiagen). RNA integrity was
verified by OD260/OD 280 absorption ratio determination (>1.9) using a Biophotometer 6131.
Total RNA was DNase-treated by amounting 1.0 pg of total RNA with 2.0 pL of buffer, 2.0 pL
of DNase I (Invitrogen, Carlsbad, CA) and DEPC water to reach a final volume of 20.0 pL.
Solutions were kept at room temperature for 15 minutes, then 2.0 pL of EDTA/Stop Solution
was added and the entire solution heat inactivated at 70°C for 10 minutes. DNase-treated total
RNA was stored at -80°C.
cDNA was made from DNase-treated total RNA by reverse transcription using random
oligo (dT)i2-i8primers (Invitrogen, Carlsbad, CA) and the Superscript™ II Reverse Transcriptase
(Invitrogen, Carlsbad, CA). Parallel samples lacking the addition of reverse transcriptase were
made alongside, herein dubbed -RT, to verify the successful removal of genomic contamination
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and integrity o f collected total RNA. Total RNA, 10 mM dNTPs (Genscript) and 250 ng/pl
random primers were heated at 65°C for 5 minutes. Samples were then chilled on ice and
centrifuged , followed by the addition o f 5x First Strand Buffer (250 mM Tris-HCl pH 8.3, 375
mM KC1 and 15 mM MgCl2) and 0.1 M DTT. Samples were then warmed for 2 minutes at 25°C
prior to the addition o f reverse transcriptase and were then further incubated an additional 10
minutes at 25°C. The reverse transcription reaction was performed at 42°C for 50 minutes,
followed by heat inactivation at 70°C for 15 minutes. Samples were treated with RNase H for 20
minutes at 37°C. cDNA was stored at -20°C.

II. B. ii. mClca RNA expression level by qRT-PCR
To compare the mClca4 and mClca6 RNA expression levels between WT and CF mice, RTquantitative PCR Analysis (qRT-PCR) was initially performed on the ilea from juvenile UNC B6
and BC mice from each genotype group, and then correspondingly on the entire GI tract from
juvenile and adult UNC B6 mice. The cDNA samples used were isolated and made as described
above (II. B. i.). All primers used for qRT-PCR were designed using OligoPerfect™ Designer
software (Invitrogen, Carlsbad, CA) and purchased from Sigma-Genosys, Oakville, ON. Primer
sequences were (mClca4) forward 5'-GTCGTCGAGATGCAAAGACA-3', reverse 5'CAGCAGACGCCTTGATTACA-3', and (mClca6) forward 5'AGTTTACGCCACCCATCAAG-3', reverse 5'-CAGATGCTGTCCTGCTGAAA-3'. To correct
for variations o f RNA quantity and cDNA synthesis efficacy, primers designed for the murine
housekeeping gene y3-actin were generated as (/3-actin) forward 5'TCGTGGGCCGCTCTAGGCACCA-3', and reverse 5'-GTTGGCCTTAGGGTTCAGGGGGGI
3'. Calculated melting temperatures o f mClca4, mClca6 and y3-actin primers ranged between
63.7- 78.4°C. Amplicon sizes were (mClca4) 213 bp, (mClca6) 139 bp, and (fi-actin) 250 bp.
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fold serial dilutions (1:5, 1:25, 1:125) of each cDNA sample were used as templates to construct
standard curves for estimation of copy numbers within each reaction tube. All PCR reactions
were performed using either Brilliant™ SYBR™ Green QPCR Master Mix or Perfecta™
SYBR® Green Supermix, Low Rox (Quanta Biosciences, Gathersburg, MD). Reactions were run
in the Mx3000P™ cycler in duplicate of each cDNA sample, $-actin cDNA samples and no
template controls for each set of primers. Optimized thermal cycling conditions were run for 45
cycles of 95°C for 30 seconds, 68°C for 1 minute and 76°C for an additional 30 seconds.
Quantitation was achieved using the analysis software MxPro by applying the adaptive baseline
and moving average algorithm enhancements according to the following formula: 1/(2a('
ACt(target)/2A(-ACt(controi)^ where ACt = (Ct of fi-actin - Ct o f mClca4/mClca6). To calculate the
relative expression level of mClca4 and mClca6, the Ct (threshold cycle) values obtained for
each genotype were compared to WT mice (control). The Mean±SEM was then calculated for
each genotype. The significance of differences between genotype (WT vs. CF) experimental
groups was assessed using an independent t-test. Results were considered significant for p=0.05.
The significance of differences between intestinal samples (duodenum vs jejunum vs ileum vs
colon) for each WT and CF experimental group was assessed using the one-way ANOVA test.
Results were considered significant for p^0.05. Follow-up tests for statistically significant
results were performed using the Tukey test. Results were considered significant for p^0.05.

II. B. iii. Tissue specific expression of the gene
Organ specific expression of mClca6 (RNA) was determined by reverse transcriptase
PCR (RT-PCR). The cDNA made as previously outlined (II. B. i.) from the lungs, heart, liver,
kidney, spleen, colon, brain, uterus, stomach and ileum from one female juvenile UNC B6
mouse was amplified by PCR using the mClca6 primers (as described in II. B. ii.). The
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aforementioned P-actin primers (see II. B. ii.) and -R T negative controls for each organ were
run alongside to ensure the integrity of the RNA. RT-PCR reactions were run using the
GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA). Optimized thermal cycling
conditions were 94°C for 3 minutes, followed by 35 cycles of 94°C for 20 seconds, 68°C for 20
seconds and 72°C for 90 seconds, and finally 72°C for 7 minutes. Samples were loaded onto a
I. 5% agarose gel, run for 30 minutes at 100V and visualized using the Pharmacia Biotech Image
Master VDS (BioSurplus Inc, San Diego, CA).

II. C. Ileal histopathology
II. C. i. Histochemistry
Ileal sections were infused and immersed in 10% neutral buffered formalin and routinely
embedded in paraffin. Paraffin embedded tissues were cut to 5 pm and sections mounted on
Superfrost®/Plus microscope slices (Fisher Scientific, Nepean, ON).
Histochemistry was performed at the Centre for Modeling Human Disease, Pathology
Core, at Mount Sinai Hospital, Toronto and at the Victoria Research Labs, London Regional
Cancer Program, London. Ileal tissues from all genotypes were stained with Periodic acid Schiff
(PAS). In brief, staining was carried out by first oxidizing in periodic acid (0.5% aqueous)
followed by washing in distilled water. The sections were then stained in Schiff s Reagent
(Sigma) for 15 minutes followed by rinsing in water. Nuclei were stained with Harris
haematoxylin followed by dehydration and mounting. Photomicrographs were taken using Image
Pro-plus 5.1 Software (Media Cybernetics), using the Leica DMRB microscope (Leica, Wetzlar,
Germany) and the 2000R Fast 1394 camera (QIMAGING Digital Cameras, McHenry, IL).
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II. D. Cftr RNA expression
II. D. i. Cftr RNA expression level by qRT-PCR
To compare the Cftr RNA expression throughout the GI tract of juvenile WT UNC B6
mice, qRT-PCR was performed on the stomachs, duodena, jejuna, ilea and colons. Total RNA
from all tissues was isolated and cDNA was made as previously outlined (see II. B. i.). Primers
specific for a 481bp fragment o f Cftr were as follows, forward 5’CATCTTTGGTGTTTCCTATGATG-3' and reverse 5'-GTAAGGTCTCAGTTAGAATTGAA3' (Invitrogen, Carlsbad, CA). Primers for f-actin are described in section II. B. ii. Calculated
melting temperature of Cftr primers ranged between 52.0- 59.0°C. QRT-PCR was performed as
outlined in II. B. ii, with the exception of an annealing temperature of 65°C for 1 minute.
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III.

Results

III. A. B6 Juvenile mice
III. A. i. Gross pathology of mice
Intestinal obstruction causes premature death in CF mice before the age o f three weeks
unless a liquid diet is implemented at the time o f weaning (72). Though the liquid diet is crucial
for juvenile survival into adulthood, it does not prevent the failure to thrive phenotype, which is
noticeable as early as two weeks o f age (63). Failure to thrive, a trait characteristic o f CF in
human patients, is caused by insufficient absorption o f nutrients due to the over-production of
mucus in the small intestine. The mucus causes blockage o f the pancreatic ducts, preventing the
secretion o f necessary digestive enzymes required for macromolecule catabolism and absorption
at the apical membrane o f the enterocytes o f the small intestine. Given that this obstructive
mucus is present at birth, it was hypothesized that at the time o f weaning, CF juvenile mice
would be significantly smaller in weight and length, compared to their juvenile WT counterparts.
The study was designed to compare five WT and five gender-matched CF juvenile mice
for size and weight measurement. An independent t-test, with a significance level o f p<0.05,
would be used to determine if the CF mice were significantly different in size and weight
compared to WT mice o f the same age. Unfortunately, breeding o f the UNC B6 litters in our
laboratory was not successful, and at the time of this experiment only a complete dataset for one
WT and one CF juvenile mouse was available from the laboratory database (Unpublished data).
In the absence o f a sufficient sample size, parametric statistical analysis could not be performed.
One WT male and one CF male mouse from the same litter were sacrificed by cervical
dislocation and their bodies weighed and their length measured for comparison. CO 2 inhalation is
the most popular method o f euthanasia, however, recent literature has not supported its use when
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harvesting lung and brain tissue due to its demonstrated pharmakinetic and histological changes
(115-118). Given the number of our studies based on lung and brain tissue, our laboratory
routinely performs cervical dislocation. Cervical dislocation is a traumatic method of
extinguishment, and can result in extravasations into the thoracic cavity if done incorrectly, but
the speed at which it is performed eliminates the risk of biochemical and histological changes
due to prolonged insult (118).
Descriptive results at the time of weaning (21 days of age) revealed that the WT mouse
weighed 11.8 g and measured 6.8 cm from nose to base of tail (Figure 3.1a). Comparatively, the
CF mouse weighed 7.6 g and measured 3.8 cm from nose to base of tail (Figure 3.1b). This is
equivalent to a 36% reduction in weight, and a 44% reduction in length, in the CF mouse. In
addition, Figure 3.1a and 3.1b are provided as a qualitative demonstration of the general gross
anatomical differences between WT and CF mice of the same age.
Given the smaller size of the CF mouse, it was suspected that mucus was present in the
GI tract. Previous literature suggests that the ileum is the most highly affected portion of the
small intestine, and often the site of fatal mucus blockages (reviewed in (57)). Ileal dissections
were grossly approximated and surgically performed by removing a portion of small intestinal
tissue adjacent to the cecum. While surgical approximation is by far the most common method of
intestinal dissection, the exact distances proximal or distal to discernible landmarks differ
between laboratories (119). Although not commonplace practice in our laboratory, the addition
of RT-PCR for the ileal tissue markers glucagon-like-peptide-1 (GLP-1), peptide YY (PYY) and
ileal lipid-binding protein (ILBP) and the histological identification of Peyer’s Patches would
have confirmed surgical approximation (120-121).

40

To confirm the presence or absence of obstructive mucus within the small intestine, a
plan was.designed to include the histological ileal sections from five WT and five CF juvenile
mice. Due to the unavailability of properly stored ileum specimens, sections could only be
obtained following dissection o f the two juvenile WT and CF male mice described in the
previous paragraph. Ileal sections were stained with Periodic acid schiff (PAS), which binds
mucin and illuminates mucus deposits. Goblet cell hyperplasia in the presence of decreased
expression levels of mCLCA3 has been reported in our laboratory (62), thus goblet cell counts
were included to determine if intestinal mucus was the result of hyperplasia or mucus over
production. As can be seen in Figure 3.1c, the WT mouse ileum has mucus, as evident by the
magenta staining, in a thin layer along the epithelial surface and within thirty-five goblet cells of
the ileum. In contrast, the CF mouse ileum’s PAS histochemistry in Figure 3.Id shows an
abundance of PAS positive mucus along the epithelial surface, within eighteen goblet cells, and
within the lumens and crypts of the ileum. Given the expansiveness of the mucus within the
crypts and lumens of the CF ileum, it seems likely that the mucus plays an integral role in the
intestinal pathology and failure to thrive phenotype of the CF mouse. However, without
additional histological samples from a larger cohort of mice, mean goblet numbers could not be
compared for statistically significant differences and these qualitative results remain suggestive
only.

III. A. ii. RNA expression studies
III. A. ii. 1. mClca4 and mClca6 RNA ileal expression level
Intestinal disease is the primary cause of death in CF mice. Severe intestinal obstruction,
most commonly within the ileum, can cause blockage, inflammation and perforation leading to
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death just after birth or at the age o f weaning. As was discussed in the Introduction, some CF
mouse models never develop the severe intestinal phenotype and have prolonged survival in
comparison, leading many experts to believe that disease-modifying genes are responsible. The
murine CLCA family o f proteins is one o f the suspected disease modifying groups. The family is
a diverse group, consisting o f six known proteins, spanning many tissues and having several
different predicted functions (82, 83-92). Previously in our laboratory, mCLCA3 has been shown
to be down-regulated in the ileum o f a CF mouse model, and when corrected through transgenic
manipulation, CF intestinal symptoms were alleviated (62). Building on this work, it was the
objective o f this study to determine if two other members o f the murine CLCA family, mCLCA4
and mCLCA6, were differentially expressed in the ileum o f a CF mouse model.
The study was undertaken to quantify ileal expression o f mClca4 and mClca6 in WT and
CF mice using qRT-PCR. [3-actin amplification was used to normalize sample results for relative
quantities o f mClca expression. Normalization o f unknown gene products against a known and
consistent reference gene is required for qRT-PCR to quantify expression levels accurately. This
is to ensure that technical error, such as improper pipette technique, does not inappropriately
skew expression levels in one sample relative to the other samples, /3-actin was selected as the
housekeeping gene for this study because o f its extensive tissue expression throughout our
mouse model, including lung, GI tract and brain, and the familiarity and previous success our
laboratory has had using the gene as the normalizing standard. While a recent study has
demonstrated that y3-actin shows inconsistent expression among villus cells, crypt cells, and
whole mucosa from the mouse small intestine (123), inconsistencies between the different
intestinal tissues were not examined, and as such many laboratories still use /3-actin as a
normalizing standard throughout the GI tract (119-122). In retrospect, using elongation factor la
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Figure 3.1. Gross pathology of WT and CF juvenile UNC B6 mice. A. WT juvenile; B. CF juvenile;
Periodic acid schiff (PAS) histochemistry on paraffin embedded tissue sections. Photomicrographs at 40x
magnification are shown for the ileum of C. WT and D. CF mice. PAS positive material is shown as a
magenta colour. Selected goblet cells have been identified with (^). Selected crypts have been identified
with ( ). WT mice have PAS reactive mucus in thirty-five goblet cells and in a thin layer along the villus
epithelium. CF mice have PAS reactive mucus in eighteen goblet cells and the crypts. A. B and D are
courtesy of unpublished data from the laboratory database.
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would have also been appropriate given its use in other mCLCA studies (87), and this would
have allowed comparisons across different studies.
Standard and dissociation curves were constructed for all primer sets using a cDNA
sample which had been previously verified as containing no genomic contamination, a
verification procedure further discussed in III. A. ii. 2. Serial dilutions of the verified cDNA
sample were used to test the efficiency of the selected primer sets. A standard curve, when
sample dilutions are plotted against their respective Ct values, should be linear, with a coefficient
of determination (R2) as close to 1 as possible. An R2 value of 1 implies the regression line
perfectly fits the data, or that for any given sample concentration, an accurate Ct value can be
predicted. Serial dilutions of primers were used to calculate the optimal concentrations of
forward and reverse primer sequences, using the verified cDNA sample. Primer concentrations
were chosen based on the primer set that had the highest amplitude on the dissociation curve,
without additional peaks or “shoulders”, which would imply primer dimers or genomic
contamination.
The standard curve and dissociation curve for fi-actin primers are shown in Figure A6.1a
and b, respectively. The standard curve for ¡3-actin has an R2 value of 0.999, indicating that the
reaction is efficient and Ct data is accurate. The dissociation curve for the p-actin primers shows
a single peak indicating a single product is being amplified (Figure A6.1b). The standard curve
and dissociation curve for mClca4 are shown in Figure A6.2. The standard curve for mClca4
primers has an R value of 0.982, indicating the reaction is efficient and Ct data is accurate. The
dissociation curve for the mClca4 primers shows a single peak, indicating a single product is
being amplified (Figure A6.2b).The standard curve and dissociation curve for mClca6 are shown
in Figure A6.3. The standard curve for mClca6 primers has an R2 value of 1.00, indicating the
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A.

Ileal Samples

Figure 3.2. QRT-PCR of ileal expression levels, normalized to /1-actin. Six UNC B6 mice were
sacrificed at 3 weeks of age. Each bar represents one mouse. A. Level of mClca4 expression and B.
mClca6 expression in WT (n=2) and CF (n=4) mice of an UNC B6 background were analyzed and
measured in ARn. Black: WT; gray: CF. Error bars represent standard deviation for duplicate runs of each
sample.
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reaction is efficient and Ct data is accurate. The dissociation curve for the mClca6 primers shows
a single peak, indicating a single product is being amplified (Figure A6.3b).
Comparative quantitation reactions were performed on CF mice compared to their WT
counterparts using qRT-PCR, and differences were determined using an independent t- test;
differences were considered significant at the p<0.05 level. The WT sample with the lowest Ct
value was selected by the MxPro3000 as the calibrator from which all other samples were
relative. As shown in Figure 3.2a, where the calibrator is designated a value of 1, no significant
difference was seen in mClca4 expression in the ilea of CF mice (0.61±0.27, Mean±SED),
compared to WT mice. In the case of mClca6, a ten-fold decrease in average expression was
observed for CF mice (0.13±0.03, Mean±SED; p<0.001) compared to their WT counterparts
(Figure 3.2b). Comparing each CF mouse individually to the calibrator, expression of mClca6
was variable, ranging from 3-39% of wild-type expression. Reductions in mClca6 expression
were more considerable compared to decreased levels previously noted for mClcai (61, 93). It
should be noted that although mClca4 levels in juvenile CF mice were found not to be
statistically significantly different compared to WT mice, possibly a result of being unpowered,
efforts were chosen to focus upon mClca6 due to the demonstrated increased statistical
significance.
To confirm the results for mClca6, the choice was made to increase the sample size. A
power calculation was conducted to determine the necessary number of mice to demonstrate a
significant difference if one was present. This would thus avoid committing a Type II error,
which entails accepting the Null hypothesis when in fact a significant difference exists. This may
occur when sample sizes are too small to detect differences between independent groups. Power
is necessary to detect a statistically significant difference, whereas effect size (ES) reports how
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big a difference it is, an important distinction. The p-value depends on both the sample size and
the ES, so a result can be found to be significant if the ES is large, despite a small sample size, or
if the sample size is large, despite a small ES. To contextualize the significance of the
differences, the amount of variation between populations can be used to determine how much
overlap is expected based on the distribution. Given the decreased variability between WT and
CF samples, due to the congenic background of the mice and the highly controlled environment,
it is reasonable to expect a large ES. Quantitatively, the ES for mClca6 expression levels can be
calculated using the data from Figure 3.2b, and finding the standardized mean difference
between the two groups (this is Cohen’s d). When this was performed, an ES of 4.9 was
calculated. A d value >3.0 is considered a large ES, and estimates that 93% of the time one
would be able to correctly identify either a WT or CF mouse based on their mClca6 expression
levels. Using the University of Western based computer program Horatio® (124), a sample size
of 13 WT and 13 CF mice was determined to be a sufficient cohort to detect a large ES at 80%
power. In other words, this study would be expected to detect a significant difference between
WT and CF mice at least 80% of the time, given a sample size of 26 total mice. The study was
therefore designed to use 13 WT and 13 CF, gender-matched juvenile mice. Independent t-tests
with a significance level of 0.05 were planned to examine potential differences. Due to
unavailability of sufficient breeding pairs, litter sizes and proportions of WT and CF mice to
heterozygous offspring, a reduced sample size of 20 mice was ultimately used; 5 WT males, 5
WT females, 5 CF males and 5 CF females. A sample size of this magnitude can find a
significant difference 68.5% of the time.
The most recent literature has not reported sex-specific expression levels for mClca6.
While our laboratory has never shown any gender-specific differences with our modifier genes,
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other laboratories have shown hormone regulation of epithelial channels (125), and thus it was of
interest to determine if this was the case with mClca6. Given the lack of reported difference
between males and females for other CLCA family members, it was hypothesized that no
significant sex difference would be found for mClca6. Within the WT group, an independent ttest was used and found no significant difference between male and female mice. Similarly,
within the CF group, no significant differences were observed between males and females. These
results allowed the collapse of genders for future studies. Figure 3.3 shows the relative ileal
expression levels of mClca6 between the WT and CF groups of mice. A significant 11-fold
reduction in expression, with a large ES, is observed for the CF group (0.34±0.10, Mean±SEM;
p<0.005), compared to the WT mice (3.58±1.03, Mean±SEM). These additional results provide
further evidence that there a significant robust difference in mClca6 expression exists between
WT and CF juvenile mice. It should be noted that the recommended sample size could not be
obtained, but the six additional mice were not required in order to detect statistically significant
differences between the two groups. Given the large ES, it is also unlikely the additional mice
would greatly bias the results. The decrease in power, from the preferred 80% to 68.5%, could
limit the study’s ability to detect statistical significance between males and females from each
group, and this should be recognized as a possible Type II error.
III. A. ii. 2. Organ expression profile of mClca6
CF manifestations occur in most of the organ systems of the body. CF patients can
present with varying degrees of severity within the lungs, GI tract, sweat glands, pancreas, liver
and reproductive system. Predominantly the respiratory system is most affected, but obstruction
in the GI tract, as Ml or DIOS, can cause morbidity and mortality. Although many mouse models
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Figure 3.3. QRT-PCR of ileal niClcaó expression levels, normalized to /i-actin. Level of mClcaó
expression in WT and CF juvenile mice from an UNC B6 background were analyzed and measured in
ARn. Dark red: WT mice (n=10); Dark blue: CF mice (n= 10). ** indicates significance difference
(p<0.005). Error bars represent standard error for biological replicates within each genotype.
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of CF are designed through deletion of the same region of the CFTR as the AF508 mutation, few
demonstrate the severe lung phenotype so characteristic of CF patients. In fact, GI pathology is
the leading cause of death in CF mouse models, especially in UNC B6 mice. Other areas of
lesser severity include the liver and reproductive tract. The uterus, unlike the vas deferens, is
severely affected in CF female mice, resulting in infertility. Although tissue expression profiles
have been performed for many of the murine CLCA family members, at the time of this study,
the expression pattern of mClca6 was yet to be identified in the UNC B6 strain. The objective of
this study was to determine in what tissues mClca6 was expressed, and if it could therefore be
involved in other CF disease manifestations. All major organs were taken into account in this
analysis, including lungs, heart, liver, brain, kidney, spleen, colon, ileum, stomach and uterus.
Special interest was placed on the GI tract, liver and uterus, as these are major sites of CF
manifestation in the mouse. It was hypothesized that mClca6 expression would be present in the
organ tissues most affected by CF disease in the UNC B6 mouse: liver, lungs, colon, ileum and
uterus. One female WT mouse was selected for sacrifice and organ harvest in order to determine
uterine expression of mClca6. Given that RT-PCR is a qualitative method of analysis for mRNA
levels, one mouse was deemed sufficient to elucidate which tissues expressed mClca6. For each
cDNA tissue sample, a duplicate tissue sample (-RT) was made that contained all of the same
aliquots of buffers, but did not have the addition of reverse transcriptase; -R T samples would
therefore not contain any cDNA. These samples could be used as a negative control for genomic
contamination, as any DNA present in the sample would be detected and amplified, and confirm
the presence of DNA not of the gene of interest. Quality of all ten cDNA tissue samples were
also controlled for by using fi-actin as a positive control to confirm the presence of cDNA within
each cDNA sample. As can be seen in Figure 3.4, following RT-PCR, mClca6 expression
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Figure 3.4. Tissue expression of mClca6 by RT-PCR. Organ tissue was harvested from a
juvenile WT female UNC B6 mouse. cDNA was made from each tissue sample, and run in the
GeneAmp PCR with mClca6 primers. Positive controls for RNA integrity were ft-act in primers,
whereas negative controls for RNA integrity were -R T samples. Samples were loaded onto a
1.5% agarose gel and run for 30 min at 100V. Expression is limited to colon, stomach and ileum.
Lu: Lung; H: Heart; Li: Liver; K: Kidney; Sp: Spleen; C: Colon; B: Brain; U: Uterus; St:
Stomach; II: Ileum; -RT: no reverse transcriptase.

appears to be conserved in the GI tract, with only a faint band appearing for the stomach, and
more prominent bands appearing within the colon and ileum tissues. Product was estimated to be
140 bp in size, which corresponded to the anticipated 139 bp product generated by the mClca6
primers. P-actin was present in all tissue samples, confirming the presence of viable cDNA.
Conversely, no bands appeared in the -R T samples, confirming the absence of genomic
contamination. It would have been beneficial quantifying band fluorescence to ensure relative
quantities of fi-actin and mClca6, but unfortunately the Pharmacia Biotech Image Master VDS
used to visualize the gel was not equipped with the necessary computer technology to perform
this task. In addition, while mClca6 expression was exclusive to the GI tract within the scope of
this study, not all murine tissues were accounted for, including but not limited to skin, pancreas,
tongue, eye, bone and muscle. As such, it cannot be concluded with absolute confidence in this
study that mClca6 is not expressed elsewhere than the GI tract, however, it should be noted that
recent literature has supported this study’s findings (87).

III. A. ii. 3. mClca6 RNA GI tract expression in WT mice
Although the ileum is predominantly the tissue most severely affected in the CF mouse
model, as evident by lethal mucus obstructions (reviewed in (57)), the entire GI tract
demonstrates histopathological changes (63). Based on the findings presented in Figure 3.4,
relative expression of mClca6 throughout the GI tract was investigated. Given the significant
difference in expression between WT and CF ileum, it was anticipated that the remaining tissue
portions of the small and large intestines would also show differential expression between WT
and CF mice. At the time of this study, there was no literature about the relative expression of
mClca6 in the WT GI tract. Based on this absence, the objectives of this thesis were two-fold.
The first purpose for investigation was based on the hypothesis that differential expression of
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mClca6 in the CF mouse model was related to CF intestinal pathology. The second purpose for
investigation was to be the initial researcher to characterize mClca6 gene expression throughout
the GI tract of WT mice.
This study harvested tissue, from stomach to colon, from five WT and five CF juvenile
mice. By convention in biomedicial research using congenic mice, a sample size of five is more
than sufficient for many studies (62, 63, 71, 83, 84), although the potential for being under
powered will be discussed in the Limitations section of the Discussion. Using qRT-PCR, relative
expression levels were calculated and compared using an independent t-test, at a significance
level of p<0.05. Intestinal dissections were performed in the same manner as described in III. A.
i. To summarize, the entire GI tract was removed, from its most proximal point (stomach) to its
most distal point (colon). Surgical approximations were performed on the duodenum, jejunum,
ileum and colon as follows: the most proximal portion of the small intestine adjacent to the
stomach was designated the duodenum, the most distal portion of the small intestine adjacent the
cecum was designated the ileum, the most distal portion of the large intestine was designated the
colon and the portion equidistant between the duodenum and ileum was designated the jejunum.
As mentioned previously, the surgical approximations performed in our laboratory are a common
method of dissection among other laboratories (119), with the exception of the jejunum. While
this study’s approach to jejunal dissection was consistent among all samples, in retrospect the
procedure could have been performed with more accuracy if jejunal sections were obtained using
the ligament of Treitz as a landmark (126). The ligament of Treitz suspends the duodenum from
the diaphragm, and is commonly referred to as the anatomical landmark of the duodenojejunal
junction. Without the guide of this landmark, or the verification using the jejunal transcription
factor GATA4 (121), it should be noted that expression level discrepancies within the jejunum
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could be the result of poor surgical technique. This will be discussed in the Limitations section of
the Discussion.
Assessment was undertaken using qRT-PCR for comparative quantitation of mClca6
expression in the stomach, duodenum, jejunum, ileum and colon of five WT mice. Relative
quantification with absolute values was performed using the MxPro3000, which involves an
arbitrarily chosen calibrator. Firstly, Ct values for all samples are normalized using an
endogenous control, in this case (3-actin. Next, all Ct values are divided by the calibrator’s Ct
value, which results in a relative value of 1.0 for the calibrator, and values either above or below
1.0 for the remaining samples. By normalizing the samples to (3-actin, variations in sample
amounts are eliminated. Furthermore, by dividing all the Ct values by the calibrator, different
hybridization probe annealing efficiencies between mClca6 and /3-actin are eliminated. The
decision was arbitrarily made to choose the stomach as the calibrator, based on its large tissue
size and thus availability for many total RNA collections, and also the assumption from Figure
3.3 that it would have the lowest expression throughout the GI tract. The latter point would
ensure that relative values of the other tissues would be in the positive direction. Alternatives of
this presentation are not uncommon (127), however, it seemed most visually appropriate to show
the progression of tissue expression through the GI tract. The five WT stomach samples were
selected as calibrators for the qRT-PCR, and by default the MxPro3000 automatically selected
the calibrator sample with the lowest Ct level a value of 1, to act as the baseline reference point
for all remaining tissues. Therefore, expression levels were normalized to the housekeeping gene
as the internal standard, and represent the relative value of mClca6 in each tissue to mClca6 in
the calibrator. The chosen stomach sample was used as the baseline reference for all future
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samples, which allowed data to be compared, contrasted and statistically analyzed across
subsequent experiments.
As can be seen in Figure 3.5, WT mClca6 expression, when compared to levels of
expression in the stomach, increased through the duodenum (268.8±72.9, Mean±SEM) and
jejunum (621.6±112.0, Mean±SEM), peaked in the ileum (917.0±123.0, Mean±SEM), and
abruptly dropped with progression into the large intestine (84.4±17.3, Mean±SEM). Given these
results, it would appear that mClca6 expression increases upon progression through the small
intestine, abruptly tapering off with progression into the large intestine. This was verified using
one-way ANOVA test, which confirmed statistical significance in mClca6 expression among all
four tissue samples (F(3,16) = 16.505,/? < 0.001). Follow-up tests were conducted to evaluate
pair-wise differences among these means. The following pairs o f tissues were determined to have
a significant difference in means, with a large ES, at the 0.05 level using the Tukey test:
duodenum/ileum, jejunum/colon and ileum/colon (Figure A6.4). In summary, the mClca6
expression pattern shown in Figure 3.5 closely follows the CF intestinal pathology pattern that
has been well documented in the literature (59, 63 and reviewed in (57)).

III. A. ii. 4. mClca6 RNA GI tract expression in CF mice
At the time of this study, no experimental data was available in the literature on relative
expression levels o f mClca6 throughout the GI tract o f CF mice. Given the significant difference
in expression levels between WT and CF ileal samples in Figure 3.3, it was hypothesized that the
remaining tissues o f the GI tract would also show differential expression. Assessment was
undertaken using qRT-PCR for comparative quantitation o f mClca6 expression in the stomach,
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Figure 3.5. Q RT-PCR of m Clca6 expression levels throughout the gastrointestinal tract,
norm alized to fl-actin. Level of mClca6 expression within the stomach, duodenum, jejunum,

ileum and colon of juvenile WT (n=5) and CF (n=5) UNC B6 mice were analyzed and measured
in ARn. Blue: WT: Green: CF. * Indicates significant difference (P<0.005). Error bars represent
standard error of samples within each tissue type.
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duodenum, jejunum, ileum and colon of five CF mice. Dissections were performed as previously
outlined in III. A. ii. 3. In accordance with their WT counterparts, expression levels within the GI
tracts of CF mice demonstrated the same tissue expression pattern, with increasing values from
stomach to ileum, and then tapering off with progression into the large intestine (Figure 3.5). CF
duodenum (140.0±29.21, Mean±SEM) and CF jejunum (338.2±68.80, Mean±SEM) showed
considerable reduction in mClca6 expression when compared to WT values for those tissues.
Only the CF ileum (378.2±37.94, Mean±SEM, p<0.005), however, was found to be statistically
significantly lower and with a large ES. CF colon (161.0±37.93, Mean±SEM) showed elevated
levels, though this was not shown to be statistically significant, possibly a result of being under
powered. A one-way ANOVA test was performed to determine if mClca6 expression levels
among the different CF tissues was significantly different. A significant difference was observed
among CF duodenum, jejunum, ileum and colon CF tissues (F(3,16) = 6.957, p = 0.003). Follow
up tests were conducted to evaluate pair-wise differences among these means. The following
pairs of tissues were determined to have a significant difference in means, with a large ES, at the
0.05 level using the Tukey test: duodenum/ileum and ileum/colon (Figure A6.5).
Although this data does not support the initial hypothesis that stomach, duodenum,
jejunum and colon tissues would also express less mClca6 than WT, it has characterized a tissue
expression pattern through the proximal to most distal portion of the GI tract. Using the ANOVA
statistical measure, significant differences are evident among the different tissues of the GI tract,
which suggests that mClca6 expression is regulated in a tissue-specific manner. Significant
differences between WT and CF juvenile mice were only found within the ileum, however,
jejunal values at p=0.063 were approaching significance and should therefore be interpreted with
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caution. Given the potential for bias being introduced due to misuse of anatomical landmarks, an
increase in sample size could either confirm or reject these findings.

III. B. B6 Adult mice
in . B. i. Gross pathology of mice
At the time of weaning, approximately 90% of CF mice kept on a solid chow diet will die
(128). If supplemented with a liquid diet, over 90% of CF mice can survive into adulthood. A
liquid diet, commonly Peptamen, is a lipid-enriched, nutritional substitute used in cases of
malnutrition, often with CF patients. Peptamen poses fewer difficulties than solid chow with its
absorption along the intestinal tract, and is much less likely to cause ileal obstruction. Studies
have shown that many of these CF mice exhibit no shortened lifespan, although they remain
smaller than their WT counterparts (129). In our laboratory, adult CF mice have been noted to no
longer require the liquid diet past the age of 6 weeks in order to survive. A study has recently
verified this phenomenon, but with only a 78% survival rate at 40 days and a 33% survival rate
at 100 days after switching to a solid chow diet (128). Although intestinal pathology is still
present in these mice, it was unclear if differential expression of key genes, such as mClca6, is
responsible for the increased survival on solid chow. It was the interest of this experiment to
determine if adult WT and CF mice were grossly different from each other based on weight and
length, and if those differences are related to histological changes within the ileum.
Histologically, it was hypothesized that the adult CF ileum would not be different than adult WT
ileum in terms of goblet cell number and quantity of mucus. This was based on the
understanding that the ability for adult CF mice to survive on a solid chow diet implied the
absence of obstructive mucus characteristic of the severely affected juvenile CF mice.
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The plan for investigating gross anatomical differences between adult mice was to
include weighing and measuring five WT and five CF adult mice, followed by statistical analysis
using the independent t-test with a significance level of p<0.05. However, no adult CF mice and
only one adult WT mouse were available for analysis at the time of this study. One adult female
WT mouse was sacrificed and characterized for comparison to CF data from our laboratory
database. At the time o f death (11 weeks of age), the WT mouse weighed 54.6 g and measured
10.5 cm from nose to base of tail (Figure 3.6a). Measurements and an ileal section from an adult
CF mouse, taken at the time of death (7 weeks o f age), revealed that it weighed 47.2 g and
measured 9.8cm from nose to base of tail, comparatively a reduction in weight of 14% and
length of 7%. While a photograph of that mouse would provide important supportive evidence,
routine photographing of our mice was not standard protocol in our lab and as such a photo was
not available to include here. It is of interest to note that differences in weight and length
diminished as the juvenile mice aged into adults. Comparing data from Figure 3.1 to Figure 3.6,
differences between WT and CF mouse weights were reduced from 36% to 14%, and mouse
lengths were reduced from 44% to 7%. Again, the accuracy o f these data cannot be confirmed
without additional mice for comparison, but it has been reported elsewhere that adult CF mice do
increase their growth rate to match their WT counterparts, although they do remain smaller in
weight and length (130).
It has been well documented that juvenile CF mice have severe intestinal pathology,
especially in the ileum, which can result in blockage and premature death (59, 63 and reviewed
in (57)). The ileal histological changes also correlate with a failure to thrive phenotype and
decreased growth compared to their WT littermates. By the age of 6 weeks, CF mice begin to
increase their rate of growth, although they do ultimately remain smaller (130). It was unclear if
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this increase in growth was related to a histological change within the ileum in adult CF mice. To
determine if this was the case, an ileal section was harvested from the adult WT female mouse
and stained with PAS. As previously mentioned in III. A. i, surgical approximations were used to
isolate ileal tissue, the accuracy o f which could have been improved with the histological
identification of Peyer’s Patches. PAS histochemistry of the one WT adult mouse from Figure
3.6a is shown in Figure 3.6b and illustrates PAS positive mucus in a thin layer along the
epithelial surface and within the goblet cells of the ileum. One hundred and thirty-six goblet cells
were counted within the WT ileum. In comparison, PAS histochemistry o f ileal tissue from an
adult CF mouse located in our laboratory illustrated PAS positive mucus solely within the goblet
cells of the adult CF ileum (Figure 3.6c). Twenty-four goblet cells were counted in the adult CF
ileum, a reduction of 82%. This reduction is most likely not an accurate reflection of ileal
pathology, but rather due to the poor quality of the adult CF section, which was improperly
stored and susceptible to tissue degradation. If an intact specimen had been obtained, the
literature suggests an increase in goblet cell number and size would have been observed in the
adult CF ileum (63, 131, 132).

III. B. ii. RNA expression studies
III. B. ii. 1. mClca6 RNA ileal expression level varies with age
Several factors play into differences in gene expression between juvenile and adult mice.
Many of these relate to hormone regulation of key genes, while others may control the growth
and maturation of tissues (133-134). Due to the propensity for CF mice to prematurely die, the
vast majority of CF research has focused on using juvenile mouse models, which has
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Figure 3.6. Gross pathology of W T and CF adult UNC B6 mice. A. WT adult; Periodic acid

schiff (PAS) histochemistry on paraffin embedded tissue sections. Photomicrographs at 40x
magnification are shown for the ileum of B. WT and C. CF mice. PAS positive material is shown
as a magenta colour. WT mice have PAS reactive mucus in 136 goblet cells ( ^ ) and in a thin
layer along the villus epithelium. CF mice have PAS reactive mucus in 24 goblet cells.
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resulted in few studies investigating CF intestinal disease in adults. Limited research exploring
why some adult CF mice, often without the supplementation of a liquid diet, have a normal life
expectancy has opened the door for novel and exciting investigative opportunities. With the
emergence of mCLCA6 as the newest member of the mCLCA family of proteins, the
opportunity arose in which to provide the first characterization of its GI tract tissue expression in
adult WT and CF mice.
It was the interest of this study to determine if mClca6 expression levels were different
between WT and CF adult mice, and between adult and juvenile mice of each genotype. The
study compared ileal samples from ten adult WT and CF mice, five of each genotype for any
statistical differences, once again using the independent t-test with a significance level of p<0.05.
Additional differences between juvenile and adult ileal samples would also be investigated using
the same statistical method. It was hypothesized that the decrease in intestinal severity in adult
CF mice would be related to increased expression levels of mClca6. QRT-PCR was performed to
assess ileal levels of mClca6 within WT and CF adult mice. Samples were normalized to p-actin,
and calibrated using the same WT juvenile stomach sample as III. A. ii. 3. Using this calibration
allowed for a direct comparison between juvenile and adult ileal values, and juvenile WT and CF
data from Figure 3.5 was included to showcase differences between the two ages. As shown in
Figure 3.7, adult WT values were significantly lower (412.00±60.57, Mean±SEM, p<0.01)
compared to juvenile WT ilea, a reduction of 55% with a large ES. Expression levels between
adult WT and CF mice were not found to be statistically significantly different, in sharp contrast
to the significant difference (p<0.005) between expression levels in juvenile WT and CF mice.
Also, ileal expression levels between juvenile CF and adult CF were not found to be statistically
different. In contrast to earlier expectations, it can be concluded that mClca6 expression is
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Figure 3.7. QRT-PCR of adult ileal mClca6 expression levels, normalized to fi-actin. Levels
of m Clca6 expression within the ilea of five WT and five CF adult UNC B6 mice were analyzed
and measured in ARn. and compared alongside those levels previously reported for ten WT and
ten CF 3-week-old mice (See Figure 3.5). Blue: WT; Green: CF. * Indicates significant
difference (p<0.005). ** indicates significant difference (p<0.01). Error bars represent standard
error for samples within each genotype.
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significantly reduced in the WT mouse as it ages, but interestingly, expression levels remained
consistent in the CF mouse.

III. B. ii. 2. mClca6 RNA GI tract expression in adult WT and CF mice
Characterization of mClca6 expression levels was furthered investigated throughout the
GI tract of adult WT and CF mice. The design of the study allowed evaluation of the expression
levels of mClca6 in the stomach, duodenum, jejunum, ileum and colon from five WT and five
CF adult mice. Statistical analysis used the independent t-test with a significance level of p<0.05,
with the additional use of the one-way ANOVA to analyze statistical differences among the
different tissues from the same genotype. It was hypothesized, as it was with the juvenile GI
tract, that a progression o f mClca6 expression would correlate with the progression of intestinal
severity. Assessment was undertaken using qRT-PCR for comparative quantitation of mClca6
expression in the duodenum, jejunum, ileum and colon tissues of five WT adult mice. Relative
expression was normalized to (t-actin, and calibrated using the same juvenile WT stomach
sample as III.A.ii.3 in order to directly compare results between juvenile and adult GI tracts. WT
mClca6 expression showed a slight variation in pattern from that previously seen in the juvenile
mouse. As shown in Figure 3.8, expression levels increased through the duodenum
(260.74±54.31, Mean±SEM), peaked in the jejunum (926.40±128.83, Mean±SEM), and abruptly
tapered off through the ileum (412.00±60.57, Mean±SEM) into the colon (249.00±61.86,
Mean±SEM). Using the one-way ANOVA test, expression levels were found to be significantly
different among the different tissues of the GI tract, confirming tissue-specific expression of
mClca6 (F(3,16) = 14.991, p O .001). Follow-up tests were conducted to evaluate pair-wise
differences among the means. The following pairs of tissues were determined to have a
significant difference in means, with a large ES, at the 0.05 level using the Tukey test:
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duodenum/jejunum, jejunum/ileum and jejunum/colon (Figure A6.6). When these results are
compared to juvenile WT GI tract values, a large ES and significant (p<0.05) 3-fold increase in
expression in the adult colon relative to the juvenile colon was observed, in addition to the 2.2fold reduction (p<0.01) in expression in the adult ileum relative to the juvenile ileum reported in
Figure 3.7. It should be noted that the shift from peak expression levels, from ileum to jejunum
as the mice age, could be an accurate reflection of changes in transcriptional regulation. It is also
possible, however, that this change could be the result of not using the ligament of Treitz, a topic
that will be further discussed in the Limitations section of the Discussion.
Further assessment was undertaken to determine if the tissue expression pattern and
expression levels of mClca6 in adult CF mice would be similar to juvenile CF mice. The study
used the duodenum, jejunum, ileum and colon tissues from five adult CF mice. Differences
between adult WT and CF expression levels, and between adult and juvenile CF mice, would be
determined using the independent t-test with a significance level of p<0.05. Differences between
tissue expressions within the CF GI tract would be determined using a one-way ANOVA.
Expression levels were detected using qRT-PCR for comparative quantitation of mClca6
expression. Samples were normalized to fi-actin, and calibrated using the same juvenile WT
stomach sample previously used in III.A.ii.3 in order to make direct comparisons between
juvenile and adult GI tracts. As shown in Figure 3.8, CF mClca6 expression showed the same
tissue expression as that seen in the adult WT mouse. Expression levels increased through the
duodenum (153.92±21.67, Mean±SEM), peaked in the jejunum (317.80±13.00, Mean±SEM),
slightly fell through the ileum (313.70±55.35, Mean±SEM) and rapidly decreased into the colon
(84.30±10.71, Mean±SEM) (Figure 3.8). This differential pattern through the tissues of the GI
tract were confirmed as being significantly different, signifying tissue-specific expression in the
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CF GI tract (F(3,16) = 14.356, /?<0.001). Follow-up tests were conducted to evaluate pair-wise
differences among the means. The following pairs of tissues were determined to have a
significant difference in means, with a large ES, at the 0.05 level using the Tukey test:
duodenum/jejunum, duodenum/ileum, jejunum/colon and ileum/colon (Figure A6.7). In
comparison to expression levels in the adult GI tract, a large ES and significant (p<0.001) 3-fold
reduction in expression in the adult CF jejunum relative to the adult WT jejunum and a large ES
and significant (p<0.05) 3-fold reduction in expression in the adult CF colon relative to the adult
WT colon was observed. Upon further investigation, adult CF expression levels of mClca6 for all
tissues were not found to be significantly different when compared to juvenile CF expression
levels.

.
In summary, adult mice showed a slightly different tissue expression than juvenile mice.

Peak expression o f mClca6 in adult mice occurred in the jejunum and not in the ileum as
previously shown for juveniles. These adult WT jejunal expression levels, however, were not
found to be significantly different compared to juvenile WT jejunal expression levels. Adult WT
jejunum and colon expression levels were significantly increased relative to adult CF jejunum
and colon. Adult WT ileal expression levels were significantly reduced compared to juvenile WT
levels, whereas adult WT colon expression levels were increased compared to juvenile WT
levels. Given these data, it is highly suggestive that the CFTR is connected to the up-regulation
of mClca6 from a tissue-specific baseline expression level, a topic that will be addressed in
further detail in the Discussion section.
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Figure 3.8. QRT-PCR of adult mClcad expression levels throughout the GI tract,
normalized to fi-actin. Level of mClca6 expression within the stomach, duodenum, jejunum,
ileum and colon of WT (n=5) and CF (n=5) adult UNC B6 mice were analyzed and measured in
ARn. The calibrator was a juvenile WT stomach sample. Blue: WT: Green: CF. * Indicates
significant difference (P<0.005). Error bars represent standard error for samples within each
tissue type.
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III. C. CFTR studies
III. C. i. RNA expression studies
III. C. i. 1. Cftr RNA GI tract expression in juvenile WT mice

Since the discovery of the CFTR in 1989, CF research studies have been dedicated to its
characterization, function and manipulation in order to better understand CF. The CFTR is
widely expressed in the respiratory tract, sweat glands, pancreas, liver, GI tract and reproductive
tract, and mutations can cause wide variation in organ dysfunction. In situ hybridization studies
have shown within the GI tract, arguably the second most severely affected organ system in CF,
CFTR expression is diffuse with expression highest in the duodenum and lowest in the colon
(42). Soon after the isolation of CFTR, the murine Cftr gene was located and CF mouse models
were generated to help in understanding the disease and provide the potential for treatment
options. Using quantitative methods, murine CFTR has been shown to be expressed largely in
the GI tract, to a lesser extent in the reproductive tract, liver, and lungs, and minimally in the
pancreas. Although its lack of clinical relevance in the lungs and pancreas afford little use of
mouse models for human pancreatic and respiratory research, the similarity in intestinal
pathology between mice and humans has been revolutionary.
Surprisingly, in light of the severe intestinal pathology that murine CFTR knockouts are
predisposed to, there are no studies quantifying Cftr expression levels using qRT-PCR. From a
study recently published, the CFTR and mCLCA6 have been found to co-localize in the large
intestine when visualized using immunofluorescence (87). Based on these findings, the CFTR
and mCLCA6 were hypothesized to function in unison together as channels for transepithelial
electrolyte secretion/absorption in the large intestine, although perhaps not with direct interaction
between the two proteins. As such, it was the interest of this study to investigate whether Cftr
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expression levels complemented the GI tract tissue expression pattern seen for mClca6. It was
hypothesized that if the Cftr and mClca6 function in unison, then a similar tissue expression
pattern would be seen for the Cftr. This tissue expression pattern was defined as an increase in
expression levels with progression through the GI tract to the ileum, and then a decrease with
progression into the large intestine.
In this study, Cftr expression levels were quantified within the same GI tract tissues from
the five juvenile WT mice used in III.A.ii.3. Statistical differences among different tissue types
would be determined using a one-way ANOVA, with a significance level of p<0.05. The
standard curve and dissociation curve for Cftr are shown in Figure A6.8. The standard curve for
Cftr primers has an R2 value of 0.935 and a slope of -0.976, indicating the reaction is efficient
and Ct data is accurate. The dissociation curve for the Cftr primers shows a strong single peak,
with the addition of smaller peaks depending on the primer concentration. Multiple peaks were
assumed to be the result of primer dimers, or the inappropriate joining of primers in the presence
of cDNA. As primer dimers can cause background fluorescence and subsequently overestimate
Ct values, primer concentrations were thus chosen which showed only one peak. QRT-PCR was
performed to assess Cftr expression levels throughout the GI tract of WT juvenile UNC B6 mice.
Samples were normalized to f-actin, and calibrated using mClca6 primers and the same juvenile
WT stomach sample in order to make direct comparisons between Cftr and juvenile expression
levels o f mClca6 in the GI tract. Relative to mClca6 expression levels in the juvenile WT
stomach, Figure 3.9 illustrates no similar pattern of Cftr expression through the duodenum,
jejunum, ileum and colon as previously reported for mClca6 (mRNA). In comparison to the
relative expression values in the hundreds seen for mClca6, Cftr expression is substantially
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Figure 3.9. QRT-PCR of Cftr expression levels throughout the GI tract, normalized to /?-

actin. Level of Cftr expression within the duodenum, jejunum, ileum and colon of five juvenile
WT UNC B6 mice were analyzed and measured in ARn. Relative expression was compared to
mClca6 expression levels in the juvenile stomach. Error bars represent standard error for samples
within each tissue type.
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lower; duodenum (2.88±0.43, Mean±SEM), jejunum (3.38±0.60, Mean±SEM), ileum
(2.42±0.27, Mean±SEM) and colon (3.09±0.51, Mean±SEM). Statistical analysis revealed no
significant difference among relative expression levels between the various sections of the small
and large intestine (F(3,16) = 0.843,/? = 0.49). The low relative expression levels of Cftr
reported here are in agreement with previous studies looking at the mRNA transcripts using in
situ hybridization (56). However, unlike these studies, expression levels were found to be the
same throughout the GI tract.

III. D. BALB/cJ mice

in. D. i. mClca6 RNA ileal expression
Different strains of mouse models with identical CFTR deleterious mutations may
present with vastly different phenotypes. For instance, UNC B6 and UNC BC mice both have an
exon 10 replacement in the Cftr causing a null gene, but lung disease is only present in the
former. In an investigation to determine what genes may be differentially expressed between the
two strains, one gene was confirmed as mClca3 (108). Northern blot studies confirmed that
mClcai was over-expressed in UNC BC lung tissue compared to UNC B6, expression was
dramatically increased in the CF UNC BC lung compared to WT UNC BC lung and that mClcai
expression was markedly reduced in the severe UNC B6 lungs. From Figure 3.4 and confirmed
by other studies, mCLCA6 is not present in lung tissue, however, given that UNC BC CF mouse
models tend not to suffer from severe intestinal disease, it was hypothesized that mClca6
expression levels could be elevated in these mice, similar to mCLCA3 levels in the lung (See
Figure 1.5). Ileal tissues from seven juvenile WT and seven CF UNC BC mice were collected
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and mClca6 expression levels quantified. Differences in mean expression levels would be
determined using the independent t-test with a significance level of p<0.05.
QRT-PCR analysis was performed on juvenile UNC BC WT and CF ileal samples and
normalized to fi-actin. Calibration was done by the MxPro3000 through default selection of the
WT sample with the lowest Ct value. During initial analysis of the WT samples, one sample was
hypothesized to be outside the normal distribution. To determine if this was the case, the Grubb’s
test was used to calculate a Z-score for the most maximally distributed value and compare it
against a critical Z-score for a specific sample size. In this case, a value with a Z-score above
2.02 would be considered significant as an outlier for a sample size of seven. It was determined
that the WT sample had a Z-score of 2.10, was in fact significant as an outlier (p<0.05), and at
the risk of statistical bias was removed from the data. As Figure 3.10 shows, with the removal of
the outlier, UNC BC CF expression levels (2.42±0.58, Mean±SEM, p=0.08) were found not to
be statistically different than those calculated for WT mice (1.06±0.31, Mean±SEM). Although
mClca6 expression levels were not found to be different between WT and CF UNC BC mice,
given the p value is approaching significance, it is possible that this study was underpowered, an
issue that will be addressed in the Limitations section of the Discussion.
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3.5

WT

CF

Figure 3.10. QRT-PCR of juvenile UNC BC ileal mClca6 expression levels, normalized to /?actin. Level of mClca6 expression in juvenile WT (n=6) and CF (n=7) mice from an UNC BC
background were analyzed and measured in ARn. Red: WT; green: CF. Error bars represent
standard error for samples within each genotype.
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IV.

Discussion
Recent studies have associated the CLC A family o f proteins with modification o f CF

intestinal severity (62, 73, 82-84, 94, 109, 110 and reviewed in (97), (102)). In the mouse model,
mCLCA3 has been implicated as a potential modifier due to its involvement with regulation of
mucus production and mucin properties (62, 84, 92, 94, 99, 103, 135). A transgenic mouse line
over-expressing mCLCA3 showed amelioration o f intestinal symptoms, further supporting the
claim that the CLCA family o f proteins is a strong candidate o f genetic modifiers (62). Based on
the encouraging results shown for mCLCA3, the research in this thesis o f the mCLCA family of
proteins focused upon characterizing mCLCA4 and mCLCA6 within the context o f a CF mouse
model. The results o f these studies showed a promising role for mCLCA6 with regards to
intestinal severity, and could lead to further understanding o f mucus based lesions in hopes of
developing better treatment options.

IV. A. Juvenile RNA expression studies
IV. A. i. mClca4 RNA expression
mCLCA4 is expressed in the small and large intestine, stomach, esophagus, uterus, lung
and heart o f the C57BL/6 strain o f mice (82). Structurally, it is closely related to mCLCAl and
mCLCA2, though mCLCA4 is unique for its presence in smooth muscle cells and is likely
associated with the CF currents recorded in that tissue (82, 84,95). In a study comparing RNA
expression levels o f the four known orthologs o f m C lcal, mClca2, mClca3 and mClca4, the
latter was found to be the most highly expressed in the GI tracts o f B6, BC and DBA/2J mice
with the mild CftrTsH(neo,m)1Hs» mutation and NMRI mice with the severe c ftr ,mlCam mutation (82).
In agreement with previous reports, this study has shown mClca4 to have the strongest ileal
transcriptional expression in the severe UNC B6 strain. Variability o f mRNA levels between

mouse strains was described in this thesis and has been demonstrated by others (84, 135). The
basis of this observation is unknown. In this thesis, mClca4 showed no significant difference in
ileal expression levels between WT and CF mice. Despite its strong ileal expression, it is likely
that mClca4 has no significant role in CF intestinal disease, an observation supported elsewhere
(84). Possible explanations could be that mCLCA4 has, with its wide and varied expression
throughout murine tissues, an essential and discrete role for normal cellular function within the
GI tract, and not one attributable to CF manifestations. It is also unlikely that mClca4 is the Ca2+activated chloride channel in question, as its presence within the smooth muscle, and not the
epithelium, does not lend itself to luminal secretion regulation (82).
IV. A. ii. mClca6 RNA expression
mCLCA6 is the most recent of the CLCA family members to be sequenced and studied,
and this is the first study implicating mCLCA6 as a possible modulator of CF. Computational
analyses have predicted mCLCA6 to be a heterodimeric glycoprotein (87). Composed of a 110
kDa N-terminal end and a 35 kDa C-terminal end, both cleavage products co-localize to the
apical membrane, though only the latter includes the hydrophobic transmembrane domain (82,
87, 95). Consistent with the novel Ca2+-activated CF current previously recorded for it, mCLCA6
could conceivably be a transepithelial ion conductor, either directly or indirectly as a modulator
of other protein channels (95). Studies have reported mClca6 (mRNA) expression in the small
intestine to be higher than mClca3 (mRNA), but less than mClca4 (mRNA) (84, 87, 95). Results
here support a strong ileal expression of mClca6 in the murine mouse model. For the first time,
the data in this thesis have also shown a significant reduction in mClca6 expression within the
ilea of UNC B6 CF mice compared to WT, substantially more than previously reported for
mClca3 (62, 94). In addition, these results raise the possibility o f the CFTR as a regulator of
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mClca6 gene expression in the ileum, given that Cftr knockouts have substantially reduced
mClca6 RNA expression. Similar to mClca4, an observed variation among mClca6 expression
was seen within each group of samples. This observation was considered to be explained by
age-dependent differential transcriptional expression of mClca genes within the male strain of
C57BL/6, however, substantial evidence is lacking. Disregarding age- and sex-dependent
determinants, this variation is as of yet attributed to unknown factors, but it has been found for
the Cftr, and is therefore not wholly unexpected (135).
IV. A. iii. Intestinal Expression of mClca6
The murine expression profile of mClca6 is subject to debate. The most recent study of
mClca6 in the C57BL/6 model reported an exclusive GI tract expression, limited to the apical
membrane of villus enterocytes and the crypts of Lieberkuhn in the large intestine (87). A
previous study with the B6SJL/J hybrid strain of mouse observed a markedly different tissue
expression profile for mClca6, including high expression in the intestine and stomach, with
lower levels in the eye, liver and spleen (95). This present study confirms an extensive GI tract
expression of mClca6 in the UNC B6 mouse, however, given that not all tissues were analyzed
for expression, it cannot be confirmed that this expression is exclusive to the GI tract. Consistent
with Bothe et al (87), relative expression levels increased from the stomach into the ileum, and
decreased through the colon. These tissue-specific expression levels of mClca6 have also been
reported for the Cftr, and are hypothesized to be the result of multiple transcription start sites
(136). Whether the mClca6 gene also contains multiple start sites cannot be confirmed in this
thesis, however, further investigations would be beneficial in better understanding in what
transcriptional regulatory control mechanisms mClca6 is involved. Lack of expression in the
lungs was anticipated as hCLCA4 is not found there either (73, 87, 96 and reviewed in 97, 102),
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and based on observations that mouse lungs are not severely affected by CF (58, 68, 69,110,
137-141), does not undermine mCLCA6 as a modulator o f intestinal disease severity.

As previously described, mClca6 RNA expression increases from the stomach to the
ileum, and decreases through the colon. This expression pattern is identical with the pattern of
increasing secretion o f mucin by goblet cells, and water and electrolytes by intestinal gland
enterocytes (141). Due to the lack o f mClca6 expression in goblet cells and the small intestinal
crypts (87), mCLCA6 is more likely to have a role in absorption, though without support of
functional studies, this is purely speculative. Under normal conditions, absorptions by the villus
enterocytes are balanced by secretions from the gland enterocytes and goblet cells (141, 142),
thus mCLCA6 could be a key regulator in maintaining an appropriate liquid state o f the lumen.

This is the first study o f its kind to show differential expression o f mClca6 within the GI
tract o f UNC B6 CF mice. The RNA expression pattern was very similar to that shown for WT
mice, with increasing relative levels from stomach to ileum, decreasing through the large
intestine. Relative expression o f mClca6 was lower in all tissues o f the CF GI tract compared to
WT save for the colon, however, it was shown to only be significantly different between WT and
CF ileum. If mCLCA6 is involved in an absorptive role, as its cellular location would indicate, it
would be expected to be present in those tissues which are highly absorptive, such as the colon.
Given the results shown in this study, it is possible that increased levels o f mClca6 result in
increased water absorption in the colon, further dehydrating the mucus. Though tempting to
theorize such a role for mCLCA6 based on its elevated levels, the large intestine is not severely
affected by CF lesions and is thus not an ideal tissue from which to determine CF modifiers.
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IV. B. Adult RNA expression studies

It has been previously reported that CF mice which reach adulthood (>6 weeks o f age),
without the supplementation o f a liquid diet, are categorized as Class III mice and suffer a milder
form o f CF (16, 18, 72). In this study, all UNC B6 mice were either Class I or Class II, and to
reach adulthood they had to be kept on a liquid diet to prevent intestinal obstructions. In
laboratory observations, adult CF mice were predominantly female, and able to survive without
complications when their diet was switched back to normal chow after that 6 week period. It was
therefore imperative to determine if mClca6 was differentially expressed in these mice compared
to their juvenile counterparts.

IV. B. i. mClca6 RNA expression in the GI tract

To date, no studies have examined mClca6 RNA expression in the GI tract o f adult UNC
B6 WT and CF mice. mClca6 expression levels increased through the duodenum and jejunum,
and sharply decreased thereafter through the remaining portions o f the GI tract. Expression levels
in CF mice were found to only be significant compared to WT in the jejunum and colon. The
jejunum is not widely investigated in the mouse model, since usually premature death occurs as a
result o f ileal obstructions. Studies using adult UNC B6 WT and CF mice have found significant
differences in potential difference (PD) and short circuit current (/sc) in the jejunum, with
evidence suggesting the basal Isc is a result o f electrogenic CF secretion, which is completely
absent in the CF model (143). The results presented here are in contrast to the expression pattern
for juvenile mice, as no significant difference was demonstrated for jejunal tissues between
juvenile WT and CF mice. An increase in sample size for juvenile and adult mice would be
useful in determining if these results are accurate, or a consequence o f insufficient power.
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The colon has been an intriguing tissue within the course of these studies given its
variability in mClca6 expression, despite the lack of disease severity. Expression levels in adult
WT colon are statistically higher than adult CF colon and juvenile WT colon, and this variability
could be attributed to changes in transcriptional regulation as the mouse ages. If this were indeed
the case, studies examining transcriptional enhancers and repressors associated with the gene
would be fundamental in support of this theory. To reiterate, the lack ofCF lesions associated
with the murine colon does weaken the clinical significance o f these findings, however, further
studies could identify regulatory aspects of mClca6 in the colon which could be beneficial in
understanding its differential expression elsewhere in the GI tract.
IV. B. ii. mClca6 RNA expression in the ileum
In contrast to the results shown for juvenile mice of the same genetic background, this
study has shown no significant difference between adult WT and CF ileal levels of mClca6.
Surprisingly, and contrary to early hypotheses, it was a reduction in WT expression levels, not an
increase in CF expression levels, which resulted in the lack of a statistically significant
difference; adult CF levels of mClca6 were the same as juvenile CF levels. It is not immediately
clear why the disparity exists between the two WT sample groups. Reasoning for the increased
expression at the time of weaning could pertain to a possible role for mClca6 as an additional Cl"
conductance requirement for avoiding ileal obstruction during pre- and peri-weaning. This would
be in conjunction with evidence of alternative Cl" channels which serve as protection against
intestinal disease severity in those mouse strains mildly affected (83, 85, 145 and reviewed in
(144)). To corroborate this theory, additional studies would need to verify up-regulation of
mClca6 between 2-5 weeks of age, as well as investigating mClca6 levels in those specific
mouse models which are severely affected. In addition, an mCLCA6 knockout mouse line would
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be expected to portray some degree of intestinal disease in the form of ileal obstruction in order
to further support this hypothesis.
The question of why CF females prevail into adulthood is much less understood, but was
consistent in this study given that of the 5 adult CF mice analyzed, 4 were female and required
gender matching within the WT group. Given that differential hormonal regulation of other
murine epithelial channels have been shown (129), it is plausible that mClca6 expression could
be estrogen-dependent once mice reach puberty. In support of this theory, the Cftr has also been
found to be differentially regulated by androgens and estrogens within the lungs and uterus (133,
134).
IV. C. Mammalian Cftr expression in the GI tract
Since the isolation of the CFTR gene in 1989, many studies have been done to determine
which tissues express it and to what degree. To date, whole genome-wide analyses are available
for many mammalian species, however, protein and RNA tissue expression have been largely
untouched. Currently, human and rat CFTR and Cftr RNA expression profiles exist, respectively,
performed by using the in situ hybridization techniques (42, 56, 146). Both species share the
same pattern of expression; a decreasing gradient of expression along the proximal to distal axis
of the intestine and along the crypt to villus axis. In addition, both transcripts exist in low-copy
numbers per cell, primarily in the CFTR high expressor cells (CHE), but they can also be located
in the apical domains of Brunner’s glands and in crypt epithelial cells. Though murine CFTR
distribution patterns have been reported (147), levels o f RNA expression throughout the GI tract
have not. It was thus paramount to determine what expression pattern the murine Cftr possessed,
and how this may relate to the co-localization earlier reported with mCLCA6.

80

IV. C. i. Cftr RNA expression in the mouse
Though the mouse model has become a crucial tool of CF research, the pathological
differences in mouse and human intestinal disease have been an issue since its inception.
Previous studies have demonstrated maximal expression in the duodenum and minimal
expression in the ileum for human and rat CFTRJCftr, respectively. These results were confirmed
using transgenic CF knockout mice expressing human CFTR, however, qRT-PCR studies have
not quantified Cftr expression levels in the C57BL/6 strain (148). In this present study, murine
Cftr RNA expression through the GI tract resembled neither mClca6 nor the patterns detailed for
human and rat CFTR/Cftr. Contrary to earlier studies with human and rat GI tracts, and results
shown here for mClca6, Cftr expression in the mouse was the same from duodenum to colon.
The main cause of this discrepancy could be based on an incorrect assumption that because mice
and rats are taxonomically from the same subfamily, gene expressions would be similar between
the two. In fact, studies have shown that gene expression can vastly differ between the two (149
153). Without in situ studies looking at Cftr expression in mice, it is not appropriate to assume
similar tissue expression based solely on both laboratory animals being from the Murinae
subfamily. Further investigation, however, has shown these qRT-PCR results to be in contrast to
a CFTR protein distribution pattern already reported for the mouse (147). It is highly likely that
this is due to an insufficient sample size, given that the Cftr has few copy numbers per cell, and a
small ES such as this requires a much larger sample size than initially proposed. Relative to
mClca6 levels from the same samples, Cftr levels are significantly decreased, which is in
accordance with evidence elsewhere (15, 147). While Bothe et al (87) did find co-localization of
mCLCA6 with the CFTR in the colonic crypts, a complementary role for the two proteins cannot
be deduced based on RNA expression.
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It seems likely that the Cftr acts, at least within the scope of this study, as a
transcriptional regulator of mClca6, though in what capacity is subject to debate. The reduction
in mClca6 expression levels could be the result of two scenarios, which will be discussed here;
reduced transcription or decreased stability resulting in accelerated degradation. Both scenarios
have been theorized as possible interactions between the CFTR and other proteins. In the case of
accelerated degradation, researchers have shown that the CFTR is required to prevent the
ubiquination of the Nrf-2 transcription factor (154). In this study, CF inflammation caused by
increased oxidative stress was linked to the decreased expression of antioxidant enzymes, which
require the transcription factor Nrf-2 to bind the antioxidant response element (ARE). Nrf-2 is
bound to the adaptor protein KEAP1, which also binds the E3 ubiquitin ligase complex. Upon
phosphorylation, hypothesized to be regulated by the CFTR, KEAP1 releases Nrf-2 into the
cytoplasm, where it is translocated to the nucleus and binds ARE. In the absence of
phosphorylation, the E3 complex ubiquinates Nrf-2 for degradation.
An mClca6 model based on this pathway is shown in Figure 4.1, where an unidentified
chaperone protein is required to stabilize the mRNA transcript from degradation. In this model,
the CFTR is required to regulate phosphorylation and the activation of the chaperone. In its
absence, the chaperone is not activated, the mClca6 transcript is not stabilized and rapid
degradation occurs. The problem with this model is that very little to no mClca6 expression
would be expected in the CF mouse model, and this is not the case shown in this thesis. In fact,
given that mClca6 expression levels between CF mice from both age groups were the same for
all tissues, it is likely the Cftr enhances transcriptional activity, and is not responsible for the
complete stabilization of the gene product. Recently, a study was published which showed a
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Figure 4.1. Proposed model of reduction in mClca6 expression levels, degradation theory. In
WT mice, the CFTR is involved in the phosphorylation (dark red circle) of an unidentified
chaperone protein (purple circle), which translocates it to the nucleus. Upon entry to the nucleus,
the chaperone binds the mClca6 (RNA), stabilizing it and preventing accelerated degradation. In
CF mice, the chaperone is not phosphorylated. does not translocate to the nucleus and cannot
bind and stabilize the mClca6 mRNA transcripts. Subsequently, the mClca6 transcripts are
degraded (yellow stars). Pink arrow: transcription.

83

WT

CF

Figure 4.2. Proposed model of reduction in mClca6 expression levels, enhancer theory . In
WT mice, the CFTR activates, through an unknown mechanism, an unidentified transcription
factor (purple circle), which translocates it to the nucleus. Upon entry to the nucleus, the
transcription factor binds the enhancer (green band) within the mClca6 gene, increasing
transcriptional activity. In CF mice, the transcription factor is not activated, does not translocate
to the nucleus and cannot bind the enhancer within the mClca6 gene. Subsequently, only baseline
expression levels o f mClca6 transcripts are made. Pink arrow: transcription.
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CFTR-dependent CREB pathway in spermatogenesis in CF patients (155). Given that CREB is a
master switch transcription factor, responsible for the transcriptional activation of many
downstream signalling pathways, it is plausible that the CFTR may regulate a transcription factor
necessary for the enhancement of mClca6 expression. A model for this is shown in Figure 4.2,
where an unidentified transcription factor is activated by the CFTR, translocates to the nucleus
and binds an enhancer in the mClca6 gene. This theory for CFTR regulated transcription factors
has been previously suggested based on a study investigating NF-kB translocation in WT and CF
mice (156). In this study, NF-kB, which regulates several cytokines involved in CF
inflammation, was found to be translocated to the nucleus in WT, but not CF mice upon a P.
aeruginosa infection. Although researchers were unable to elaborate on how the CFTR may
activate NF-kB, the model presented in this thesis would support the baseline levels of mClca6
expression seen in CF juvenile and adult mice. Alternatively, the up-regulation of ENaC
regulatory subunits in CF nasal tissue has been documented elsewhere, and also highlights a
direct correlation between CF and mRNA levels of an epithelial ion channel, albeit reversely
from what is proposed here for mClca6 (157).
This theory is not wholly unfounded given that the pathology of CF cannot be fully
explained by the loss of CF conductance alone. The CFTR must then have pleiotrophic functions
outside of its own role as an ion channel. There is much evidence in support of the CFTR as a
conductance regulator; CFTR facilitates intracellular uptake of ATP required for ORCC function
(158) , inhibits Na+ absorption across the apical membrane thus preventing luminal dehydration
(159) and acts as a regulator of ROMK activity (160). In addition, the CFTR has been implicated
as a mediator of gene expression for proteins involved in chaperoning, cell growth and
development, inflammatory response and ion transport (161-165). Without knowing what
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function mCLCA6 has, it is entirely speculative to what interactions, if any, the two proteins may
have in the small intestine and distal colon. Evidence here, however, does support a relationship
between mClca6 gene expression and the presence of functional CFTR.

IV. D. mClca6 RNA expression in the BALB/cJ ileum
Strain-dependent differences in CF mouse models are common and have led to the
identification of several genetic modifiers of the disease (56, 60, 66-68, 71, 110, 111, 114, 166).
Specifically, the BC strain has shown a greater survival rate than the B6 strain, even with the
same mutation (i.e. Cftrtm,UNC) (56, 66-68, 71). Genome analysis of lung tissue between UNC B6
and UNC BC WT and CF mice revealed 31 genes which were differentially expressed between
the two strains, including mClca3 (109). The UNC B6 CF model revealed a significant reduction
in mClcaS expression, whereas the UNC BC strain showed over-expression of the gene in the CF
model. Though studies have yet to implicate mCLCA3 as the secondary genetic modifier
responsible for the rescue of lung disease in UNC BC mice, studies have shown the amelioration
of intestinal disease due to its over-expression in the UNC B6 model (61).
Given mCLCA3’s up-regulation in the mildly affected UNC BC strain, this thesis was
concerned with determining if mClca6 RNA expression was also up-regulated in CF mice from
an UNC BC background. Dissimilar to what was found by Chung et al (109), and what has been
previously demonstrated in the ileum of juvenile UNC B6 within this study, mClca6 was not upregulated in the UNC BC CF mice when compared to levels in WT mice. Though not conclusive,
these results do support further investigation into the possibility of mCLCA6 as a pivotal player
in intestinal disease severity, much like mCLCA3 has been shown in the UNC B6 strain.
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IV. E. Limitations
IV. E. i. Insufficient sample sizes
Every effort was made to obtain the ideal sample size in order to be confident with the
accuracy of the data and subsequent interpretations. Sample size is dependent on several factors:
the variability of the samples, the ES of the differences between samples, the power to detect
these differences and the error rate. Prior to every study, the necessary sample size was
calculated in order to confirm statistical significance with a power of 80% at an error rate of 5%.
In spite of this, many laboratories have used smaller sample sizes of mice than what was
recommended following statistical calculations (62, 63, 71, 83, 84). Most often, the increased
time and cost of resources to obtain calculated sample sizes of mice was cited as the primary
reason for the use of smaller sample sizes. It has now become accepted that larger sample sizes
are not required for inbred mouse studies to the same degree as other populations, such as
humans. New literature has shown that smaller sample sizes can be used with inbred mice
without compromising power because of the decrease in genetic variability within the population
(167). For many of the studies in this thesis, a sample size of five mice was deemed sufficient
given the inbred status of the mice, the large ES and the error rate. In retrospect, a larger sample
size could have been necessary to avoid a Type II error, which likely occurred in Figures 3.5 and
3.10. Given this, an increase in sample size would be appropriate and necessary for future
studies.
Figures 3.1 and 3.6 were meant to illustrate the gross and histological differences
between WT and CF mice of both ages. Size, weight, goblet cell count and location of mucus
would have served as the measured parameters for statistical analysis. At the time these mice
were needed for study, lack of care and resources had caused irreparable damage and insufficient
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numbers were ultimately obtained. Given this, it is recognized that the data collected could not
be analyzed, and is therefore not confirmed of any clinical relevance. Inclusion of the data in the
thesis was chosen as a means of presenting the original intentions of the study, the methodology
and statistical analysis that would have been performed given an adequate sample size and what
may have been inferred from the results.
IV. E. ii. Small intestine dissection
Our laboratory has routinely performed GI tract dissections without the addition of any
histological, anatomical or biochemical markers as verifiers of position. The chosen method of
small intestine dissection entailed removal of tissue sections which were grossly approximated
according to proximal and distal portions of the GI tract. Exact measurements from anatomical
landmarks were not used in our laboratory, which are often used in others (119). These
measurements include the removal of duodenal tissue 1 cm from the pyloric sphincter of the
stomach, jejunal tissue 3-5 cm from the ligament o f Treitz and ileum tissue 3-5 cm from the ileocaecal junction. Although few studies use biochemical or histological confirmation of their tissue
samples, it appears that correct anatomical approximation is widely accepted as an appropriate
means of dissection.
Without the aid of the ligament of Treitz, jejunal sections in this thesis were susceptible
to being inaccurate reflections of jejunal tissue. Given the sections were removed equidistant
between the duodenum and ileum sections, it was thought that the jejunal sections could in fact
be portions of the proximal ileum. This assumption was based on the understanding that in
humans, the jejunum and ileum are roughly the same length (168). Based on the dissection
protocol used in this thesis (See Figure 4.3a), there was an increased possibility a section of
proximal ileum could have been removed as jejunum.
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Figure 4.3. Dissection protocol. A. Dissection protocol used in this thesis. The small intestine
was divided into three equal parts between the stomach and cecum. One cm sections were
removed at the proximal end for the duodenum, distal end for the ileum and equidistant between
the two for jejunum (red lightning). B. The divisions of the small intestine. The ligament of
Treitz (yellow arrow) denotes the duodenal-jejunal junction, the ileo-cecal junction denotes the
end of the ileum (green arrow) and the red arrow approximates where the jejunal-ileal junction is
situated.
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Fortunately, this is not the case in the laboratory mouse; the jejunum is double the length of the
ileum (Figure 4.3b) (169). With the additional length of the jejunum, the dissection protocol used
would have removed a portion of the jejunum, not ileum, and therefore jejunal tissue samples are
accurate representations of the murine small intestine.
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V. Summary and Future Directions
There is still much left unknown about the CLCA family of proteins, and what roles they
may possess in influencing CF intestinal disease. This thesis has shed light on mCLCA6 as a
genetic modifier of CF in the UNC B6 mouse model. Much like results previously shown for
mCLCA3, mClca6 RNA expression is reduced in the small intestine of juvenile UNC B6 CF
mice. Specifically, ileal reductions of mClca6 expression are significant, which may correspond
to the severity of intestinal disease reported in that tissue. A reduction in jejunal expression is
also seen in the mildly affected adult CF mouse. Ileal levels, however, were no longer found to
be significant, which could indicate a protective role for mCLCA6 during the pre- and periweaning period. In addition, mClca6 RNA expression levels were not found to be significantly
different between WT and CF mice from a BALB/cJ background, a strain notorious for a mild
presentation of the disease.
This thesis has only laid the foundation for the many additional investigations which
must be undertaken in order to establish mCLCA6 as a potential modifier of CF intestinal
disease. The relationship between the CFTR and mCLCA6 will need to be elucidated, and the
following studies would reveal what interaction these two proteins may have. If the CFTR is a
transcriptional regulator, as it has been proposed here, then it will need to be made clear if the
mCLCA6 is a primary or secondary gene target. Primary transcriptional regulation refers to, in
this case, that the CFTR regulates mCLCA6 expression through direct transactivation.
Alternatively, secondary transcriptional regulation refers to the CFTR regulating another protein,
a transcription factor for instance, which in turn up-regulates mCLCA6. This could be
determined through the following experiment using the murine epithelial C l27 cell line, which
stably expresses CFTR. After transfection with mCLCA6, cells would be divided into two
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categories: experimental cells exposed to cycloheximide (CHX) and control cells not exposed to
CHX. CHX inhibits protein synthesis by blocking translocation of tRNAs, thus preventing the
elongation step of translation. QRT-PCR and Western blot analysis of known CFTR targets, such
as the ENaC subunits, would confirm the presence of transcription, but the loss of translation due
to CHX. Biotin-labelled cRNA would be synthesized from the total RNA, hybridized to the
GeneChip Mouse Gene 1.0 ST Array and computationally analyzed using Affymetrix software,
such as Genechip 3.3. If comparisons between the control and experimental cell expressions of
mClca6 were unchanged in the presence of CHX, then it is a primary gene target of the CFTR. If
mClca6 expression levels were decreased in the experimental cells exposed to CHX, then this is
suggestive of mCLCA6 being a secondary gene target of the CFTR.
To validate the proposed enhancer model, identification of an enhancer element within
the mClca6 gene is necessary. This could be performed two-ways: using a reporter gene or
comparative sequence analysis. The former method would include random insertion of a reporter
gene, such as lacZ, near the suspected enhancer region of the mClca6 gene. Insertion near the
enhancer would result in the transcription and translation of lacZ whenever mClca6 transcription
is activated. Alternatively, the genomes from several different species (human, mouse and chick
for example) can be aligned and non-coding conserved regions can be identified. These
conserved enhancer regions are then joined to a reporter gene, such as green fluorescent protein,
injected into a transparent embryo and the mRNA is tracked using in situ hybridization.
The intent of the RNA in situ hybridization is to confirm the location of mClca6 (mRNA)
within the enterocytes and to determine if it is relocated in CF tissue. Efforts for RNA in situ
hybridization studies have begun with the design of primers for the 3’UTR region of mClca6
(mRNA). The 3’UTR region is ideal given that it is specific to each family member, which has
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been confirmed using a BLAST search. The primers amplify a region 1215 bp in length between
1716-2930 nt in mClca6 (mRNA). The primers have been used to amplify the mClca6 3’UTR
region during RT-PCR, and then product was purified from the gel and digested with EcoRI.
EcoRI was chosen as the restriction enzyme given its sticky ends and that no other EcoRI cut
sites are present in the mClca6 transcript. The pBluescript KS plus will ultimately hold the
ligated cDNA, and a Dig-labelled probe will be constructed.
Confirming RNA expression patterns, especially in the CF models, with protein analysis
will be the next crucial step. Ileal protein samples have already been prepared from ten WT and
ten CF juvenile mice for Western Blot analysis, in addition to the design of a N-terminus
antibody to recognize the sequence WKDSPQYRRPKQES within the mCLCA6 protein. This
probe has been verified by its use in other mCLCA6 studies (87). In addition to this quantitative
analysis, revealing protein structure through crystallography will be fundamental in determining
what functional role mCLCA6 plays in the intestinal tract, whether secretion, absorption or an as
of yet unexplored alternative. Ultimately, transgenic manipulation of the UNC B6 mouse strain
will be vital in revealing what significance mCLCA6 function has with respect to intestinal
disease severity. A knock-out model of mCLCA6 and a mCLCA6 over-expressing mouse model
would help clarify what role mCLCA6 has to play, if any, as a secondary genetic modifier. A
knock-out model could be designed similar to the UNC B6 strain, in which an insertion has been
made into one of the coding exons of mClca6 (gene), preventing viable protein. Alternatively, a
transgenic mouse over-expressing mCLCA6 could be constructed similar to the TgrlFABPmCLCA3 strain already in our laboratory. The rIFABP is specific for intestinal expression, and
could be cloned, alongside the full-length mCLCA6, into the pSl plasmid. The purified
transgene construct would then be injected into the pronuclei of C57BL/6 oocytes, and
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transgene-positive pups would be identified. Through subsequent breeding, those lines able to
transfer the construct to their offspring would be selected to be maintained on an inbred
C57BL/6 genetic background and eventually crossed with the UNC B6 strain. Through these
additional investigations, further insights into the functional roles mCLCA6 may play with
regards to CF manifestations could prove to be the next chapter in unravelling the mysteries of
CF genetic modifiers, and lead into new developments of therapeutic approaches to treating this
disease.
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VI. Appendix

Figure A6.1. QRT- PCR controls for /t-actin. A. Standard curve for fi-actin primers. The Ct
(threshold cycle) is plotted against the initial quantity of cDNA. Samples are serially diluted
cDNA from a wild-type mouse (left to right: 1:5. 1:25. 1:125). B. Dissociation curve for fi-actin
primers. The melting temperature for the PCR products in each sample from the standard curve
is plotted.
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Figure A6.2. QRT-PCR controls for mClca4
A. Standard curve for mC!ca4 primers. The Ct (threshold cycle) is plotted against the initial
quantity of cDNA. Samples are serially diluted cDNA from a wild-type mouse (left to right: 1:5.
1:25. 1: 125). B. Dissociation curve for mClcu4 primers. The melting temperature for the PCR
products in each sample from the standard curve is plotted.
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Figure. A6.3. QRT-PCR controls for mClcab
A. Standard curve for mClca6 primers. The Ct (threshold cycle) is plotted against the initial
quantity of cDNA. Samples are serially diluted cDNA from a wild-type mouse (left to right: 1:5.
1:25. 1:125). B. Dissociation curve for mClca6 primers. The melting temperature for the PCR
products in each sample from the standard curve is plotted.
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M u ltip le C o m p a r is o n s

Value
Tukey HSD
95% Confidence Interval
Mean
Difference (I
fh GrouD
1.00

J)

fJl GrouD
2.00
3.00

2.00

3.00

4.00

-352.80000

Std. Error
144.20960

Sia.
.108

Lower Bound
-765.3865

UDDer Bound
59.7865

-648.20000'

144.20960

.002

-1060.7865

-235.6135

4.00

184.36000

144.20960

.589

-228.2265

596.9465

1.00

352.80000

144.20960

.108

-59.7865

765.3865

3.00

-295.40000

144.20960

.212

-707.9865

117.1865

4.00

537.16000'

144.20960

.009

124.5735

949.7465

1.00

648.20000'

144.20960

.002

235.6135

1060.7865

2.00

295.40000

144.20960

.212

-117.1865

707.9865

4.00

832.56000'

144.20960

.000

419.9735

1245.1465

1.00

-184.36000

144.20960

.589

-596.9465

228.2265

2.00

-537.16000'

144.20960

.009

-949.7465

-124.5735

3.00

-832.56000'

144.20960

.000

-1245.1465

-419.9735

*. The mean difference is significant at the 0.05 level.
Value

Tukey H SD a
Subset for alpha = 0.05
N
5

1
84.4400

1.00

5

268.8000

2.00

5

3.00

5

GrouD
4.00

Sig.

2

3

268.8000
621.6000

621.6000
917.0000

.589

.108

.212

Means for groups in homogeneous subsets are
displayed.
a. Uses Harmonic Mean Sample Size = 5.000.

Table. A6.1. Tukey test following one-way ANOVA analysis of juvenile WT GI tract. A
one-way ANOVA test determined statistically significant differences between different tissues
from the juvenile WT group. Posthoc analysis using a Tukey test determined that statistically
significant differences in means at the 0.05 level occurred between duodenum and ileum,
jejunum and colon, and ileum and colon. Group 1.00: duodenum; Group 2.00: jejunum; Group
3.00: ileum; Group 4.00: colon.
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M u ltip le C o m p a r is o n s

Value
TukeyHSD
95% Confidence Interval

ill GrouD
1.00

Mean
Difference (IJf
-198.24000

Std. Error
72.73380

Sia.
.065

Lower Bound
-406.3329

Upper Bound
9.8529

-238.24000'

72.73380

.022

-446.3329

-30.1471

4.00

-21.06000

72.73380

.991

-229.1529

187.0329

1.00

198.24000

72.73380

.065

-9.8529

406.3329

3.00

-40.00000

72.73380

.945

-248.0929

168.0929

fJl GrouD
2.00
3.00

2.00

3.00

4.00

4.00

177.18000

72.73380

.110

-30.9129

385.2729

1.00

238.24000'

72.73380

.022

30.1471

446.3329

2.00

40.00000

72.73380

.945

-168.0929

248.0929

4.00

217.18000'

72.73380

.039

9.0871

425.2729

1.00

21.06000

72.73380

.991

-187.0329

229.1529
30.9129
-9.0871

2.00

-177.18000

72.73380

.110

-385.2729

3.00

-217.18000'

72.73380

.039

-425.2729

*. The mean difference is significant at the 0.05 level.
Value

TukeyHSD3
Subset for alpha = 0.05
5

1
139.9600

4.00

5

161.0200

2.00

5

338.2000

3.00

5

Group
1.00

Sig.

N

2

338.2000
378.2000

.065

.945

Means for groups in homogeneous
subsets are displayed.
a. Uses Harmonic Mean Sample Size =
5.000.

Table. A6.2. Tukey test following one-way ANOVA analysis of juvenile CF GI tract. A one
way ANOVA test determined statistically significant differences between different tissues from
the juvenile CF group. Posthoc analysis using a Tukey test determined that statistically
significant differences in means at the 0.05 level occurred between duodenum and ileum and
ileum and colon. Group 1.00: duodenum; Group 2.00: jejunum; Group 3.00: ileum; Group 4.00:
colon.
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Value

TukevHSD
95% Confidence interval

m G toud

1.00

2.00

3.00

4.00

fJ1 Grouo
2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00

Mean
Difference ftJ)
-665.66000'
-151.26000
11.74000
665.66000"
514.40000'
677.40000*
151.26000
-514.40000*
163.00000
-11.74000
-677.40000*
-163.00000

Std. Error
130.00371
130.00371
130.00371
130.00371
130.00371
130.00371
130.00371
130.00371
130.00371
130.00371
130.00371
130.00371

Siq.
.001
.657
1.000
.001
.006
.000
.657
.006
.604
1.000
.000
.604

Lower Bound
-1037.6032
-523.2032
-360.2032
293.7168
142.4568
305.4568
-220.6832
-886.3432
-208.9432
-383.6832
-1049.3432
-534.9432

Uooer Bound
-293.7168
220.6832
383.6832
1037.6032
886.3432
1049.3432
523.2032
-142.4568
534.9432
360.2032
-305.4568
208.9432

*.The mean difference is significant at the 0.05 level.

Value

TukevHSD3
Subset for alpha = 0.05
Groun
4.00

N
5

1
249.0000

1.00

5

260.7400

3.00

5

412.0000

2.00

5

Sig.

2

926.4000
.604

1.000

Means for groups in homogeneous
subsets are displayed.
a. Uses Harmonic Mean Sample Size =
5.000.

Table. A6.3. Tukey test following one-way ANOVA analysis of adult WT GI tract. A one
way ANOVA test determined statistically significant differences between different tissues from
the adult WT group. Posthoc analysis using a Tukey test determined that statistically significant
differences in means at the 0.05 level occurred between duodenum and jejunum, jejunum and
ileum, and jejunum and colon. Group 1.00: duodenum; Group 2.00: jejunum; Group 3.00: ileum;
Group 4.00: colon.
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Value
Tu key H SD
95% Confidence Interval
ill Group
1.00

2.00

3.00

4.00

iJl GrouD
2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00

Mean
Difference fi
di
-163.88000'
-159.78000'
69.62000
163.88000'
4.10000
233.50000"
159.78000'
-4.10000
229.40000'
-69.62000
-233.50000'
-229.40000'

Sid. Error
48.84267
48.84267
48.84267
48.84267
48.84267
48.84267
48.84267
48.84267
48.84267
48.84267
48.84267
48.84267

Lower Bound
-303.6198
-299.5198
-70.1198
24.1402
-135.6398
93.7602
20.0402
-143.8398
89.6602
-209,3598
-373.2398
-369.1398

Sig.
.019
.022
.503
.019
1.000
.001
.022
1.000
.001
.503
.001
.001

Upper Bound
-24.1402
-20.0402
209.3598
303.6198
143.8398
373.2398
299.5198
135.6398
369.1398
70.1198
-93.7602
-89.6602

*. The mean difference is significant at the 0.05 level.
Value

TukevHSD3
Subset for alpha = 0.05
Grouo
4.00
1.00

N
5

1
84.3000

5

153.9200

3.00

5

2.00

5

Sig.

2

313.7000
317.8000
.503

1.000

Means for groups in homogeneous
subsets are displayed.
a. Uses Harmonic Mean Sample Size =
5.000.

Table. A6.4. Tukey test following one-way ANOVA analysis of adult CF GI tract. A one
way ANOVA test determined statistically significant differences between different tissues from
the adult CF group. Posthoc analysis using a Tukey test determined that statistically significant
differences in means at the 0.05 level occurred between duodenum and jejunum, duodenum and
ileum, jejunum and colon and ileum and colon. Group 1.00: duodenum; Group 2.00: jejunum;
Group 3.00: ileum; Group 4.00: colon.
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Figure. A6.4. QRT-PCR controls for Cftr
A. Standard curve for Cftr primers. The Ct (threshold cycle) is plotted against the initial quantity
ofcDNA. Samples are serially diluted cDNA from a WT mouse (left to right: 1:5, 1:25. 1:125).
B. Dissociation curve for Cftr primers. The melting temperatures for the PCR products in each
sample from the standard curve are plotted.
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